registration & preliminary program - Confex

The Premier Event in Rheumatology will be in ChicaGO!Why Join Us?...2For Networking OpportunitiesOpening Event at the Field Museum of Natural HistoryExplore the Field Museum with its encyclopedic collection of culturalobjects and biological specimens from around the world. Be sureto come hungry as we will be featuring “A Taste of Chicago” menu.Space is limited, so purchase your ticket today! See page 3 for moreinformation.Connect with Peers in the Poster and Exhibit HallsLocated adjacent to each other, this year’s poster and exhibithalls will each offer a number of lounge areas providing placesto meet with peers while learning about the current advances inrheumatologic research and technology.Lunch-Time is a Great Time for Health ProfessionalsParticipate in the ARHP Networking Forum, a discipline-specificforum designed to provide an opportunity for attendees tomeet colleagues within their discipline. Also, plan to attend theincreasingly popular ARHP Networking at Noon, where you canchoose to participate in one of 30 topic discussions.ACR Study Groups – A Professional Networking OpportunityTake advantage of these sessions, designed to bring togetherattendees with a common interest in a single disease, a groupof related disorders or a specialized field of study. Participate ininformative discussions or become enlightened by new perspectives.This is your opportunity to make contacts and exchange ideas. Allmeeting attendees are welcome! See page 65 for more information.For Diverse and InnovativeSession FormatsThe ACR Knowledge BowlIn addition to returning favorites such as the Year in Review,Curbside Consults – Ask the Professors, The Great Debate andThieves’ Market, the 2011 program is introducing an exciting newsession: the ACR Knowledge Bowl. This competitive session format– in the style of the classic television game show, Jeopardy – isdesigned to test knowledge and encourage team building. It is sureto become an instant favorite.Welcome to Chicago’sMcCormick Place, thepremier conventionfacility in North America.Intimate Education SettingsIf you are looking for an opportunity to meet with a thought leaderor learn a new skill, consider a Meet the Professor or Workshopsession. These sessions are designed to provide an intimate settingfor consultation or hands-on training with leading experts in avariety of interest areas. Seating is limited for these sessions.Secure your ticket today. See page 65 for more information.Pre-Conference CoursesMake the most of your annual meeting experience. Considerattending a pre-conference course on Friday and Saturday,November 4–5. Seven pre-conferences will be offered and eachcourse is designed to offer attendees, information on a specific area.See pages 20-25 for a complete list of pre-conference courses, topicsand course details.Keep Your Educational Goals on “Track”Use the education track designations to help you navigate themeeting and identify topics that will meet your educational needs.Use the NEW Tracks-at-a-Glance handout to help you readily identifythose sessions that will be of importance to you. Visit My ACR atwww.rheumatology.org/annual to view or download the handout.It’s ConvenientAbstracts Available on Flash DriveChoose to receive your copy of the abstract supplement on a flashdrive or as a printed book. For your added convenience, use MyACR at www.rheumatology/annual to browse abstracts prior themeeting.Child Care and Nursing Mother’s RoomBring the whole family to Chicago. The ACR has arranged withKiddieCorp to provide child care at this year’s meeting. This programaccepts children six months to 12 years old. Also, a staffed NursingMother’s Room will be available at McCormick Place West. See page51 for more information.Printed Pre-Conference Course SyllabiWe heard you loud and clear. Pre-conference course syllabi will beprinted and distributed on site to registered course attendees.SessionSelectExperience the annual meeting your way – on your time!SessionSelect is the online resource that allows you to view or reviewsessions at your leisure. Register for the annual meeting and receiveFREE access to hundreds of hours of educational content includingconcurrent abstract sessions – over $500 of added value. See page49 for more information.WiFi Access and Recharge AreasComplimentary Wi-Fi access and re-charge areas will be availablethroughout McCormick Place West and in the back of some largesession halls. See page 52 for more information.Visit My ACR at www.rheumatology.org/annual to plan your schedule and view up to date session, abstract and syllabi information.

egistration & preliminary programDesignation Statement: This activity has been approved for AMAPRA Category 1 Credit.International Physicians: International physicians, who register aspart of a group and require AMA PRA Category 1 Credit(s), mustprovide the following information to your tour leader: full name,mailing address, telephone and fax numbers, and e-mail address.The information will be used to verify your meeting attendance.Health Professionals: Certificates of participation will be availableto attendees participating in an activity designated for AMA PRACategory 1 Credit.For non-CME sessions, attendees may also request a certificate ofparticipation.ACR Disclosure PolicyIt is the policy of the American College of Rheumatology to ensurethat its CME activities are independent and free of commercialbias. To ensure content objectivity and balance, and guaranteethat the content presented is in the best interest of its learnersand the public, the ACR requires that everyone in a positionto control content disclose all relevant relationships with anycommercial interest if the relationship is financial and occurredwithin the past 12 months. If there are relationships that create aconflict of interest, these must be resolved in accordance with theACR’s CME Resolution of Conflict policy prior to the participation ofthe individual in the development or presentation of CME content.Note: Disclosure information will be available prior to the activityin My ACR.DisclaimerThis annual meeting is sponsored by the American Collegeof Rheumatology for educational purposes only. The material presentedis not intended to represent the only or the best methods appropriatefor the medical conditions being discussed, but rather is intended topresent the opinions of the authors or presenters, which may be helpfulto other healthcare professionals at arriving at their own conclusions andconsequent application. Attendees participating in this medical educationprogram do so with full knowledge that they waive any claim they mayhave against the ACR for reliance on any information presented duringthese educational activities. The ACR does not guarantee, warrant orendorse any commercial products or services.NAVIGATING THE MEETINGEducational TracksThis program has been cataloged by educational tracks which are designed to help you identify the most relevant content based onyour specialty.7To navigate the meeting by track, look for these icons:BRBUSINESS OF RHEUMATOLOGYCCLINICALc/rCLINICAL AND RESEARCHcPCLINICAL PRACTICEEd.EDUCATORSfFELLOWS-IN-TRAININGPPEDIATRICSP/CPEDIATRICS AND CLINICALrRESEARCHVisit My ACR at www.rheumatology.org/annual to plan your schedule and view up to date session, abstract and syllabi information.

friday, november 47:00 am 7:30 am 8:00 am 8:30 am 9:00 am 9:30 am 10:00 am 10:30 am 11:00 am 11:30 am 12:00 pm 12:30 pmresearchclinicalclinical practiceACR Musculoskeletal Ultrasound Course for Rheumatologists - Day OneACR Certified Rheumatology Coder Course - Day Oneclinical &researchsaturday, november 5researchclinicalclinical practiceARHPclinical &research7:00 am 7:30 am 8:00 am 8:30 am 9:00 am 9:30 am 10:00 am 10:30 am 11:00 am 11:30 am 12:00 pm 12:30 pmContinentalBreakfastContinentalBreakfastContinentalBreakfastContinentalBreakfastContinentalBreakfastACR Basic Research Conference - Day TwoACR Review CourseACR Musculoskeletal Ultrasound Course for Rheumatologists - Day TwoARHP Clinical Focus CourseACR Clinical Research ConferenceACR Certified Rheumatology Coder CourseExam - Day Two8sunday, november 6BS - Basic Science Symposium; CC - Concurrent Session; CS - Clinical Symposium; Ed. - Educator Series;7:00 am 7:30 am 8:00 am 8:30 am 9:00 am 9:30 am 10:00 am 10:30 am 11:00 am 11:30 am 12:00 pm 12:30 pmresearchBS - Epigenetic Changes inRheumatic DiseaseSOTA - HenchLecture: Resolutionof InflammationSOTA - Pain,the Brain, andOsteoarthritisclinical &researchSS - Year in ReviewSS - ACR REF Oscar S.Gluck MD, MemorialLectureshipIU - New Targets inRheumatoid Arthritis:Syk, Jaks, BtkPlenary Session I: Discover y 2011Abstract Presentationsclinicalclinical practiceMA - Lipid LoweringTherapy 2011CpediatricsSOTA - NewAutoinflammatorySyndromesclinical &pediatrics

schedule-at-a-glance by dayIU - Immunology Updates for the Clinicians; MA - Medical Aspects of Rheumatic Diseases PI - Practice Issues ; SOTA - State-of-the-Art Lecture; SS - Special Session1:00 pm 1:30 pm 2:00 pm 2:30 pm 3:00 pm 3:30 pm 4:00 pm 4:30 pm 5:00 pm 5:30 pm 6:00 pm 6:30 pm 7:00 – 10:00 pmSS - Publishing inPeer-ReviewedMedical JournalsSS - Medical Education:Year in ReviewSS - ACR REF Clinician ScholarEducator PresentationsACR POSTER SESSION AACR and ARHPConcurrent AbstractSessionsACR and ARHPConcurrent AbstractSessionsMeet the Professors SessionsWorkshopsMeet the Professors SessionsWorkshopsSS - ARHP NetworkingForumCC - Rehabilitation for theClinicianCC - AxialSpondyloarthritis: NewConceptsCC - Disability: Clinical Facts,Legal Fictions, and PracticeStrategies BRCC - Rheumatic DiseaseUpdate: RelapsingPolychondritisCC - Deconstructing theRandomized ControlledTrial: Assessing the StudyQuality of Level OneNon-drug StudiesCC - Iatrogenic Misadventuresin Osteoporosis Treatment11InnovationTheaterEXHIBITS AND REPLAY CAFÉInnovationTheaterIndustry Roundtable-Supported SymposiaIU - Immunology Updates for the Clinicians; MA - Medical Aspects of Rheumatic Diseases PI - Practice Issues ; SOTA - State-of-the-Art Lecture; SS - Special Session1:00 pm 1:30 pm 2:00 pm 2:30 pm 3:00 pm 3:30 pm 4:00 pm 4:30 pm 5:00 pm 5:30 pm 6:00 pm 6:30 pm 7:00 – 10:00 pmBS - Rheumatoid Arthritis:Where Does it Begin?BS - Fibrosis: NovelParadigmsSS - ACR REF Edmond L. Dubois,MD, Memorial LectureshipSS - ACR REF Marshall J. Schiff,MD, Memorial LectureshipSS - The Earliest Phases ofRheumatoid Arthritis: Updateon American and EuropeanInitiativesVisit My ACR at www.rheumatology.org/annual to plan your schedule and view up to date session, abstract and syllabi information.

monday, november 7continuedBS - Basic Science Symposium; CC - Concurrent Session; CS - Clinical Symposium; Ed. - Educator Series;7:00 am 7:30 am 8:00 am 8:30 am 9:00 am 9:30 am 10:00 am 10:30 am 11:00 am 11:30 am 12:00 pm 12:30 pmclinicalSOTA - CervicalSpine Surgeries inRheumatic Diseases:2011 UpdateCS - Treatment ofLupus NephritisCS - Curbside Consults -Ask the ProfessorscPclinical practicepediatricsSS - ClinicopathologicConferencecPI - The Road to MeaningfulUse and Beyond: A SimpleOverview of a Complex TopicCS - Juvenile IdiopathicArthritis: Clinical Heterogeneityand the Genomeclinical &pediatricsMA - Anemia ofInflammatory DiseasecP12educatorbusiness ofrheumatologyPI - RAC and Roll: Howto Perform ComplexChart AuditscP CabstractsACR/ARHPPOSTER TOURSACR/ARHP POSTER SESSION BACR/ARHPPOSTER TOURSacr specialsessionsmtp &workshopsMeet the Professor SessionsWorkshopsWorkshopsCC - SleepDisturbance inFibromyalgiaCC - RheumaticDisease Update:MusculoskeletalManifestiationsof HumanImmunodeficiencyVirusGS - ARHPDistinguishedLecturesSS - ARHPNetworkingForum at noonarhpCC - New andNoteworthy:Nursing, Pharmacyand PedorthicsCC - Preparing forTransition from DayOne of Diagnosis toAdult CareCC - ICD Coding -Crash Course forResearchers BRCC - Antimalarials forRheumatic Disorders:Historical Perspectives,Clinical Insights andFuture Directions

monday, november 7continuedBS - Basic Science Symposium; CC - Concurrent Session; CS - Clinical Symposium; Ed. - Educator Series;7:00 am 7:30 am 8:00 am 8:30 am 9:00 am 9:30 am 10:00 am 10:30 am 11:00 am 11:30 am 12:00 pm 12:30 pmarhp continuedCC - Behave Yourself!Practical Applicationof CognitiveBehavioral Theoriesto Motivate Change inPatients with ArthritisCC - To P or Not to P?Knowing When theP-Value is Less thanUsefulindustry/exhibitstuesday, november 8InnovationTheaterEXHIBITS AND REPLAY CAFÉBS - Basic Science Symposium; CC - Concurrent Session; CS - Clinical Symposium; Ed. - Educator Series;InnovationTheater7:00 am 7:30 am 8:00 am 8:30 am 9:00 am 9:30 am 10:00 am 10:30 am 11:00 am 11:30 am 12:00 pm 12:30 pmresearchSOTA -Complimentary Rolesfor Complement inRheumatic DiseasesSOTA - NewInsights into BoneRemodelingSOTA - NeutrophilRecruitment byIntravascular DangerSignalsSOTA - Cytokineand ChemokineRegulation of ChronicPainBS - Towards Prevention ofAtherosclerosis Progression inRheumatoid Arthritis: Insightsinto the Relationship betweenInflammation and CardiovascularDisease14clinical &researchIU - GeneticDefects, AIRE andAutoimmunitySS - ACR REFPaul Klemperer,MD MemorialLectureship:Plenary Session III: Discovery2011clinicalMA - Celiac Disease:Immunopathogenesisand Clinical SpectrumPotentialCS - Emerging Conceptsin the InflammatoryMyopathiescP cP PCS - The Three P’s ofDermatologic andAutoimmune Disease:Pyoderma, Panniculitis andPemphigus/PemphigoidcPclinical practiceSOTA - Omega 3 FattyAcids in Inflammationand CardiovascularHealthc/rCS - Spondylarthropathies:Recent InsightsCclinical &pediatricseducatorSS - Gender Issues in theRheumatology WorkforceBRCS - Periodic Feverswith AphthousStomatitis,Pharyngitis, andAdenitisbusiness ofrheumatologyPI - UnderstandingMedicare IncentivePrograms:e-Prescribing & PQRICcPPI - CORC Forum: PaymentReform OptionsCcP

schedule-at-a-glance by dayIU - Immunology Updates for the Clinicians; MA - Medical Aspects of Rheumatic Diseases PI - Practice Issues ; SOTA - State-of-the-Art Lecture; SS - Special Session1:00 pm 1:30 pm 2:00 pm 2:30 pm 3:00 pm 3:30 pm 4:00 pm 4:30 pm 5:00 pm 5:30 pm 6:00 pm 6:30 pm 7:00 – 10:00 pmEXHIBITS AND REPLAY CAFÉInnovationTheaterWine and Cheese ReceptionIU - Immunology Updates for the Clinicians; MA - Medical Aspects of Rheumatic Diseases PI - Practice Issues ; SOTA - State-of-the-Art Lecture; SS - Special Session1:00 pm 1:30 pm 2:00 pm 2:30 pm 3:00 pm 3:30 pm 4:00 pm 4:30 pm 5:00 pm 5:30 pm 6:00 pm 6:30 pm 7:00 – 10:00 pmBS - Mechanisms ofLymphoma Development inSystemic Autoimmune DiseaseBS - Next-GenerationSequencing Applied toRheumatic DiseasesBS - Osteoarthritis: A Disease ofthe Joint as an OrganBS - New Concepts in theAutoimmune Pathogenesis ofInterstitial Lung DiseasesCS - Developing ACR Guidelinesfor the Treatment of Gout15CS - Vasculitis: Key Issues forthe Clinician in Three UniqueDiseases cPCS - The NeuromuscularSystem in OsteoarthritisSS - ACR Knowledge BowlcPCS - Extra GlandularManifestations of Sjögren’sSyndromeCS - Hyperuricemiaand Gout:Mechanisms andMorbidity (ClinicalReview) CCS - Challenging Complicationsof Systemic Sclerosis CSS - CORC: Insurance RoundtableCCS - The Child withChronic PainSS - EducationRedesign for TeachingRheumatologistsFBRPI - MasteringPatient Flow toImprove PracticeOperationsCcPVisit My ACR at www.rheumatology.org/annual to plan your schedule and view up to date session, abstract and syllabi information.

schedule-at-a-glance by dayIU - Immunology Updates for the Clinicians; MA - Medical Aspects of Rheumatic Diseases PI - Practice Issues ; SOTA - State-of-the-Art Lecture; SS - Special Session1:00 pm 1:30 pm 2:00 pm 2:30 pm 3:00 pm 3:30 pm 4:00 pm 4:30 pm 5:00 pm 5:30 pm 6:00 pm 6:30 pm 7:00 – 10:00 pmACR/ARHP POSTER SESSION CLate-Breaking AbstractsACR Concurrent AbstractSessionsACR and ARHP ConcurrentAbstract SessionsSS - ACR LeadershipTownhall & BusinessMeetingACR Study GroupsMeet the Professors SessionsWorkshopsMeet the Professors SessionsWorkshopsCC - ExtrarticularManifestations ofRheumatoid Arthritis:Ophthalmologic, Pulmonaryand CardiovascularCC - Metabolic BoneDiseaseCC - Practice PotpourriCC - Beyond Pain and Fatigue:Expanding Clinician andResearcher Focus to ImproveDaily LifeCC - Keep People withArthritis Working: AnInteractive Case-basedDiscussionCC - Improving HealthMeasurement inRheumatologyCC - Designing ExercisePrescriptions for Individualswith Arthritis and OtherComorbidities: What arethe Considerations?17EXHIBITS AND REPLAY CAFÉInnovationTheaterIndustry Roundtable-Supported SymposiaIU - Immunology Updates for the Clinicians; MA - Medical Aspects of Rheumatic Diseases PI - Practice Issues ; SOTA - State-of-the-Art Lecture; SS - Special Session1:00 pm 1:30 pm 2:00 pm 2:30 pm 3:00 pm 3:30 pm 4:00 pm 4:30 pm 5:00 pm 5:30 pm 6:00 pm 6:30 pm 7:00 – 10:00 pmVisit My ACR at www.rheumatology.org/annual to plan your schedule and view up to date session, abstract and syllabi information.

wednesday, november 9continuedBS - Basic Science Symposium; CC - Concurrent Session; CS - Clinical Symposium; Ed. - Educator Series;7:00 am 7:30 am 8:00 am 8:30 am 9:00 am 9:30 am 10:00 am 10:30 am 11:00 am 11:30 am 12:00 pm 12:30 pmclinicalCS - Hereditary Angioedemaclinical &pediatricsCS - Efficacy and Safetyof Calcium and Vitamin DSupplementationCS - Update on Safety Issues inthe Treatment of RheumaticDiseases – From the FDA andBeyondeducatorbusiness ofrheumatologyPI - ICD-10 and HIPAA5010 – Ready or NotIt’s Coming!CcPSS - Career Opportunitiesin Rheumatology:Making a ChoiceFabstractsARHP ConcurrentAbstract SessionsACR Concurrent AbstractSessionsACR and ARHP ConcurrentAbstract SessionsCC - Highlightsfrom the 2011ARHP SessionsCC - ChronicNon-bacterialOsteomyelitisCC - Lower ExtremityMusculoskeletal Assessmentof the Rheumatology Patient18CC - Brain Correlatesof Chronic PainCC - Analysis ofLarge Databases:RheumatologyResearchOpportunitiesCC - Policy and EnvironmentalStrategies to Support IncreasedPhysical Activity for Adults withArthritis: Findings from a Centersfor Disease Control/ArthritisFoundation Expert PanelarhpCC - RubbingElbows with theHigher Ups: EffectiveCommunications withAdministrationc/rCC - Introductionto ComparativeEffectivenessResearch StudyDesigns forRheumatologyHealth ProfessionalsCC - MarketingCommunity-basedPrograms to PrimaryCare Practices: AnApproach Based onCenters for DiseaseControl AudienceResearchindustry/exhibits

schedule-at-a-glance by dayIU - Immunology Updates for the Clinicians; MA - Medical Aspects of Rheumatic Diseases PI - Practice Issues ; SOTA - State-of-the-Art Lecture; SS - Special Session1:00 pm 1:30 pm 2:00 pm 2:30 pm 3:00 pm 3:30 pm 4:00 pm 4:30 pm 5:00 pm 5:30 pm 6:00 pm 6:30 pm 7:00 – 10:00 pm19Industy-Supported Post Confrence SymposiaVisit My ACR at www.rheumatology.org/annual to plan your schedule and view up to date session, abstract and syllabi information.

ACR/ARHP PRE-CONFERENCE COURSES2:45 - 3:00 pmBreakSession IV: Successes in Rheumatology Comparative EffectivenessResearch2:45 - 4:00 pmModerator: To be announcedRegistries/Cohorts that Have Made a Difference in RheumatologyKimme L. Hyrich, MD, PhDThomas A. Medsger, Jr., MDLaura E. Schanberg, MDFrederick Wolfe, MD4:00 - 5:00 pmNetworking Reception with Poster PresentationsCACR REVIEW COURSE8:00 am - 4:00 pmPre-conference courses require a separate registration fee. Fees include a continentalbreakfast and boxed lunch. See registration form on page 67.7:00 am - 8:00 amContinental BreakfastModerators: Mary E. Cronin, MDGregory C. Gardner, MDNeuropsychiatric Lupus8:00 - 8:45 amSpeaker: Michelle A. Petri, MD, MPHNeeds Assessment:The diagnosis and treatment of neuropsychiatric lupus is difficult for all whocare for patients with systemic lupus erythematosus. There has been progressmade in the diagnosis of these disorders with nineteen defined syndromes currently.The proposed pathogenesis is of these conditions is varied as well.Upon completion of this session, participants should be able to:• describe an appropriate evaluation of a patient with possibleneuropsychiatric lupus• recall current proposed pathogenic mechanisms of neuropsychiatric lupus• devise a treatment protocol for long term management of neuropsychiatriclupusLarge Vessel Vasculitis 20118:45 - 9:30 amSpeaker: Philip Seo, MD, MHSNeeds Assessment:Large vessel forms of vasculitis are important causes of morbidity and mortalityworldwide. Diagnosis of these entities can be challenging due to the lack ofserologic testing and the inability of obtaining diagnostic tissue for severalvarieties of disease. This session will update clinicians on the pathophysiology,diagnosis, treatment and disease monitoring for the major forms of large vesselvasculitis including giant cell arteritis, Takayasu’s arteritis, and isolated inflammatoryaortitis.Upon completion of this session, participants should be able to:• describe the basic immunology associated with large vessel vasculitis and itsimplications on clinical manifestations• develop a diagnostic plan for someone suspected of having a large vesselform of vasculitis• construct a therapeutic plan for a patient with large vessel vasculitisPeripheral Neuropathies for the Rheumatologist9:30 - 10:15 amSpeaker: Julius Birnbaum, MDNeeds Assessment:Peripheral neuropathy is a common clinical problem with over a hundredpossible causes. It is often seen in patients with rheumatic diseases. Rheumatologistsmust be aware of the variety of neuropathies that can occur the settingof autoimmune disease and be able to differentiate from non immune relateddisease.Upon completion of this session, participants should be able to:• describe the classification of peripheral neuropathies• outline a diagnostic approach for patients with symptoms of neuropathy• discuss a therapeutic plan for patients with autoimmune related disease10:15 - 10:45 amBreakInflammatory Eye Disease and the Rheumatologist10:45 - 11:30 amSpeaker: James T. Rosenbaum, MDNeeds Assessment:Many rheumatic diseases have ocular manifestations and inflammatory eyedisease may be the presenting manifestation. Rheumatologists are also calledupon to assess patients with inflammatory eye disease for underlying rheumaticdisease and to provide treatment for patients with isolated inflammatory eyedisease due to skills as immunotherapists. This session will focus on the majorforms of inflammatory ocular disease with an eye toward differential diagnosis,diagnostic evaluation, and treatment of these diseases.Upon completion of this session, participants should be able to:• describe basic ocular anatomy and interpret ophthalmologic examinationterminology• formulate a differential diagnosis for common forms of inflammatory eyedisease• construct a diagnostic evaluation for patients with inflammatory oculardisease• describe the current treatment options for these illnessesPM Lessons Learned from Fibromyalgia Regarding theMechanisms and Treatment of Chronic Pain11:30 am - 12:15 pmSpeaker: Daniel J. Clauw, MDNeeds Assessment:The rheumatologist sees patients with chronic pain on a daily basis. Fibromyalgiais a common diagnosis made by rheumatologists but many other patientsdeal with chronic pain as well. The treatment of chronic pain is difficult andrequires a variety of therapeutic approaches.Upon completion of this session, participants should be able to:• describe a diagnostic approach to the patient with chronic pain• summarize the current knowledge on the mechanism of chronic pain• manage patients with chronic pain with a focus on the possible mechanismof pain in an individual patient12:15 - 1:15 pmBoxed LunchEnthesopathy: Spondylarthropathies and Beyond1:15 - 2:00 pmSpeaker: Dennis McGonagle, MB, PhDSATURDAYn o v e m b e r 5 , 2 0 1 1Visit My ACR at www.rheumatology.org/annual to plan your schedule and view up to date session, abstract and syllabi information.23

ACR/ARHP PRE-CONFERENCE COURSESSATURDAYn o v e m b e r 5 , 2 0 1 1Needs Assessment:The enthesis is an important anatomic site in the pathophysiology of the spondylarthropathygroup of diseases. It also plays a role in other rheumatic diseasesas well. This session will emphasize the anatomy, physiology, and the rheumaticdisease associations of the enthesis in order to give the practicing rheumatologista deeper understanding of the diseases we are called on to diagnosis andtreat.Upon completion of this session, participants should be able to:• describe the basic anatomy and physiology of the enthesis• describe the immunology of inflammation at the enthesis• discuss with a colleague or patient how inflammation of the enthesis isimportant in the clinical manifestations of diseaseSjögren’s Syndrome: Not Just Dryness2:00 -2:45 pmSpeaker: Judith A. James, MD, PhDNeeds Assessment:Sjögren’s syndrome is an autoimmune disorder that can vary from naggingproblems of dryness to severe multisystem disease. Rheumatologists must knowwhen to evaluate for more serious disease and the diverse ways serious diseasecan present.Upon completion of this session, participants should be able to:• outline an appropriate work up of a patient with sicca syndrome• discuss the current proposed mechanisms pathogenesis of Sjögren’ssyndrome• employ appropriate therapeutic management of the patient with Sjögren’ssyndrome2:45 -3:15 pmBreakWhen Your Defense Can’t Go on the Offense: Immunodeficienciesfor the Practicing Rheumatologist3:15 - 4:00 pmSpeaker: Troy R. Torgerson, MD, PhDNeeds Assessment:There is a growing list of immunodeficiencies that may be associated withrheumatic manifestations that the rheumatologist may be asked to address.The purpose of this session is to familiarize the practicing rheumatologist withthe common immunodeficiency syndromes and to provide a framework toevaluate patients with suspected disease.Upon completion of this session, participants should be able to:• describe to a colleague the basic components of the immune system• describe symptoms and signs that might suggest an immunodeficiency• develop a focused evaluation of the patient with possibleimmunodeficiencyc/R PMARHP CLINICAL FOCUS COURSE:TARGETED APPROACHES TO COMPLEX PAINMANAGEMENT8:00 am - 4:30 pmPre-conference courses require a separate registration fee. Fees include a continentalbreakfast and boxed lunch. See registration form on page 67.Needs Assessment:The ACR Task Force for Pain Management identified the need to increasethe level and expertise of rheumatology health professionals in order to moreeffectively treat the pain of their patients. Traditionally there has been limitedtraining in pain management in rheumatology although pain is the cardinalmanifestation of rheumatic disease. This deficiency was confirmed by theACR Pain Management survey of health professionals conducted in 2009.Moreover, technological advances in the field of neuroscience have resultedin an increased understanding of the mechanisms underlying pain that haveimplications for treatment. Therefore, consistent with the ARHP mission toimprove the knowledge and performance of rheumatology health professionals,participants completing this course will learn about the latest thinking regardingthe pathophysiology of pain, comprehensive pain assessment and how toincorporate into clinical practice evidenced-based pain management strategiesthat are guided by the mechanistic characterization of pain.Upon completion of this session, participants should be able to:• describe the advances in the understanding of pain pathophysiology,especially the mechanistic characterization of pain• identify how current pain research pertains to conceptualizing and treatingpatients with rheumatic disease• conduct a comprehensive pain assessment including addressing medicaland psychiatric comorbidities, as well as cultural, gender and age-relatedfactors• incorporate the use of validated pain assessment instruments and outcomemeasures into clinical practice• formulate evidence-based pharmacologic and non-pharmacologic treatmentstrategies based on pain mechanism and unique patient characteristics• demonstrate how concepts and strategies presented over the session canbe used to address even the most complex cases of rheumatologic patientswith pain7:00 - 8:00 amContinental BreakfastIntroduction and Overview8:00 - 8:15 amSpeaker: Afton L. Hassett, PsyDPain: Pathophysiology and Clinical Assessment8:15 - 10:15 amPain Pathophysiology: Advances in the Basic Science of PainYvonne C. Lee, MDPain in Rheumatologic PopulationsDaniel J. Clauw, MDClinical Assessment of PainElizabeth G. Salt, PhD10:15 - 10:30 amBreakComplex Pain Issues: Comorbidities and Special Populations10:30 - 2:00 pmMedical ComorbiditiesLeslie J. Crofford, MDPsychiatric ComorbiditiesLesley M. Arnold, MDPain in PediatricsLaura E. Schanberg, MDnoon - 1:00 pmBoxed LunchPharmacologic Management of Rheumatologic Pain: A MechanisticApproachKamala M. Nola, PharmD24

ACR/ARHP PRE-CONFERENCE COURSES • ACR/ARHP SCIENTIFIC SESSIONSEvidence-based Non-pharmacological Interventions2:00 - 4:30 pmPhysical Strategies: Physical Therapy, Occupational Therapy and ExerciseJan K. Richardson, PT PhDVerbal Strategies: Patient Education, Cognitive Behavioral Therapy, andComplementary Alternative MedicineDavid A. Williams, PhDCommittee will be on hand to provide advice to assist you in planning how toget the most out of your first annual meeting.This session is not eligible for CME credit. Coffee and tea will be provided.Moderators OrientationThis session is not eligible for CME credit. Coffee and tea will be provided.ACR BASIC SCIENCE SYMPOSIUM3:00 - 3:15 pmBreakCases Presentations: Targeted Approaches to Complex Pain ManagementSpeakers: Daniel J. Clauw, MDKamala M. Nola, PharmD, MSDavid A. Williams, PhDJan K. Richardson, PT, PhD, OCSWrap-upAfton L. Hassett, PsyDBR cP ACR CERTIFIED RHEUMATOLOGY CODEREXAMINATION – DAY TWO11:00 am - 5:00 pmPre-conference courses require a separate registration fee. Fees for the examinationinclude a boxed lunch. See registration form on page 67. View needs assessmentand learning objectives on page 20. This course is not eligible for CME credit.ACR/ARHP OPENING LECTURE AND AWARDS5:00 - 6:30 pmFinding and Interpreting Your Inner FishSpeaker: Neil H. Shubin, PhDNeeds AssessmentThe field of Rheumatology is composed of physicians and scientists interestedin musculoskeletal medicine. Whereas clinical medical care requires a deepunderstanding of the pathology and pathophysiology of human disease, anunderstanding of the evolutionary development of the spine and limbs givescritical perspective to the adaptations across evolutionary time that have culminatedin the human form, and may provide insight into the form and functionof the human skeleton.Upon completion of this session, participants should be able to:• trace the comparative anatomy and evolution of the spine• describe the importance of fins in the evolution of limbs• review the developmental genetic evidence and paleomorphology revealingthe “inner fish” in humansACR/ARHP OPENING EVENT7:00 - 10:00 pmFor more information, see page 3.7:30 - 9:00 amr Epigenetic Changes in Rheumatic DiseaseEpigenetic Changes in Rheumatic Disease: Focus on T cellsJohn J. O’Shea, MDEpigenetic Changes in Rheumatic Disease: Focus on B cellsHans-Martin Jack, PhDEpigenetic Changes in Synovial Fibroblasts in Rheumatoid ArthritisCaroline Ospelt, MDUpon completion of this session, participants should be able to:• discuss epigenetic mechanisms in different cell types• describe pathogenetic pathways that are activated by epigenetics inrheumatic diseases• identify therapeutic options that arise from modulation of epigeneticchangesACR SPECIAL SESSION7:30 - 8:30 amc/R PSYear in ReviewClinical PerspectiveLeslie J. Crofford, MDBasic Science PerspectiveDavid A. Fox, MDUpon completion of this session, participants should be able to:• discuss selected recent publications on the pathophysiological basis ofrheumatic diseases by literature review of important publications• describe selected treatment modalities for rheumatic diseases from therecent published literature• enumerate how these new advances may impact the practice ofrheumatologyACR STATE-OF-THE-ART LECTURE7:30 - 8:30 amr 2011 Hench Lecture: Resolution of InflammationSpeaker: Charles Serhan, PhDUpon completion of this session, participants should be able to:• describe the cellular and molecular basis of inflammation• appraise how inflammation becomes pathological• describe a family of novel mediators that restrict inflammation and restorenormal homeostasisSATURDAYn o v e m b e r 5 , 2 0 1 1SUNDAYn o v e m b e r 6 , 2 0 1 1SUNDAY, NOVEMBER 6, 2011ARHP SPECIAL SESSIONS7:00 - 8:00 amFirst-time Attendees OrientationFirst -time ARHP annual meeting are invited to an orientation to learn the ‘insand outs’ of the annual meeting. The ARHP Membership and NominationsACR REF SPECIAL SESSION7:30 - 8:30 amc/R ACR REF Oscar S. Gluck, MD, Memorial Lectureship: Everythinga Rheumatologist Should Know about Glucocorticoid-Induced BoneFragility, but Was Afraid to AskSpeaker: Nancy E. Lane, MDVisit My ACR at www.rheumatology.org/annual to plan your schedule and view up to date session, abstract and syllabi information.25

ACR/ARHP SCIENTIFIC SESSIONSUpon completion of this session, participants should be able to:• distinguish how glucocorticoid-induced bone loss differs frompostmenopausal osteoporosis• describe how glucocorticoids influence bone cell lifespan, activity and cellfate• identify how glucocorticoids alter bone quality and increase fracture risk• evaluate how effective bone active medications can prevent and reverseglucocorticoid-induced bone fragilityACR MEET THE PROFESSOR SESSIONS7:45 - 9:15 amFor more information, see page 60.ACR MEDICAL ASPECTS OF RHEUMATICDISEASES9:00 - 10:00 amC cP Lipid-Lowering Therapy 2011Speaker: Neil J. Stone, MDUpon completion of this session, participants should be able to:• describe current concepts in lipid pathophysiology and its impact oncardiovascular disease• recognize the various approaches available to manage this pathophysiology• identify best practices in management of lipid abnormalities in theirrheumatic disease patientsSUNDAYn o v e m b e r 6 , 2 0 1 1ACR WORKSHOPS7:45 - 9:45 amFor more information, see page 62.ACR PRACTICE ISSUES8:30 - 10:00 amBR C cP Health Information Technology and Informatics toPromote High Quality Rheumatologic CareThe Innovation Agenda and Health Information TechnologySpeaker to be announcedBringing it All Together: Adoption, Implementation and Meaningful UseCharles M. King II, MDUpon completion of this session, participants should be able to:• explain the forces in the current health care environment promotingadoption of health information technology• cite the types of problems in clinical practice and health care delivery thatmay be amenable to improvement with appropriate use of informationtechnology• explore the technologies and related initiatives that are improving patientcare• evaluate technology-driven opportunities to enhance care coordinationand workflow efficiencies• explain workflow systems and patient care software that you canimplement within your organizationACR IMMUNOLOGY UPDATES FOR THECLINICIANS9:00 - 10:00 amc/R New Targets in Rheumatoid Arthritis: Syk, Jaks and BtkSpeaker: Iain B. McInnes, PhDUpon completion of this session, participants should be able to:• define the basic factors and cell types involved in these pathways, and theinflammatory responses they control• explain the rationale for the development of new agents that target thesepathways• review recent clinical trial results and appreciate the potential benefits andtoxicities that have been reportedACR PRACTICE ISSUES9:00 - 10:00 amcP BR Utilizing Media Relations to Build Your PracticeIt’s All in the Planning: Determining Your Goals, Objectives andAudiencesJana Leigh Thomas, MPAEstablishing and Nurturing Important Media RelationshipsStanley B. Cohen, MDMedia Interviews: Moving from Local Rheumatologist to Go-To ExpertJana Leigh Thomas, MPAPanel DiscussionUpon completion of this session, participants should be able to:• describe the basics of media relations and how working with local mediacan help promote your practice, and rheumatology as a whole• identify different ways to use media relations tactics to promote theirpractices in their communities• develop and maintain communication with local media e.g., buildingrelationships, pitching stories, writing Letters to the Editor, etc., andposition themselves as a go-to resource for media and other constituenciesin their community• integrate the ACR’s public relations campaign, and its tools, to educatepeople in their communities on the value and role of rheumatology(nationally) and the value and role of their practices (locally)ACR STATE-OF-THE-ART LECTURES9:00 - 10:00 amp New Autoinflammatory SyndromesSpeaker: Marco Gattorno, MD, PhDUpon completion of this session, participants should be able to:• summarize current understanding of the pathogenesis ofautoinflammatory syndromes• identify clinical patterns consistent with new autoinflammatory syndromes• discuss available treatmentr PM Pain, the Brain, and OsteoarthritisSpeaker: A. Vania Apkarian, PhDUpon completion of this session, participants should be able to:• summarize regional changes in the brain associated with osteoarthritis pain• review the complex nature of osteoarthritis-associated pain• explain the current data on pain perception in osteoarthritis26ACR POSTER SESSION A AND POSTER TOURS9:00 am - 6:00 pmPoster presenters will be available from 9:00 - 11:00 am. Poster tours will be held9:00 - 9:45 am and 10:15 - 11:00 am. Morning snacks will be available from 9:00 -10:30 am.

ACR/ARHP SCIENTIFIC SESSIONSARHP GENERAL SESSION I – KEYNOTE ADDRESS9:30 - 10:30 amc/R Sleep for Success! Everything You Must Know about Sleep,but Are Too Tired to AskSpeaker: James B. Maas, PhDUpon completion of this session, participants should be able to:• determine common causes of sleep deprivation and the consequences asthey relate to thinking, performance, health and lifespan• identify the five different stages of nocturnal sleep and their importanceto daytime functioning• explore recent brain imagery research data on thinking and performance• establish strategies to improve sleep qualityEXHIBITS AND REPLAY CAFÉ10:00 am - 5:00 pmACR WORKSHOPS10:30 am - 12:30 pmFor more information, see page 62.INNOVATION THEATER10:30 - 11:15 amInnovation Theater presentations will be listed in My ACR atwww.rheumatology.org/annual in early September.c/R ACR PLENARY SESSION I: DISCOVERY 201111:00 am - 12:30 pmACR REF Industry Roundtable AwardsACR Abstract Presentation and CommentariesARHP CONCURRENT SESSIONS11:00 am - 12:00 pmc/R Best Practices for Collaboration in Research and Clinical PracticeSpeaker: Holly Falk-Krzesinski, PhDUpon completion of this session, participants should be able to:• describe how collaboration can be used in clinical practice and researchsettings• describe the Input-Processes-Output model of effectors for collaborations• describe the facilitators and challenges of collaboration and how tomaximize the benefit of collaborationC Immunology 101 and Targeted Therapies for RheumatologyHealth Care ProfessionalsSpeaker: Troy R. Torgerson, MD, PhDUpon completion of this session, participants should be able to:• describe the four compartment model of the immune system• review what happens to immune cells when they are activated• review each immune compartment in detail• describe current and emerging therapies that target each immune systemcompartmentC Rheumatic Disease Update: Calcium Pyrophosphate CrystalDeposition DiseaseSpeaker: Frédéric Lioté, MD, PhDUpon completion of this session, participants should be able to:• discuss the signaling pathways that are activated by calcium pyrophosphatedihydrate crystals• review potential therapeutic targets related to calcium pyrophosphatedihydrate crystal-induced inflammation• develop a treatment plan for patients with chronic and recurrent calciumpyrophosphate dihydrate arthritisc/R The Osteoarthritis Initiative: A Database for Knee OsteoarthritisResearchOverview of the Osteoarthritis Initiative: Study Design and CurrentResultsMichael C. Nevitt, PhDCollaboration with the Osteoarthritis Initiative: Obtaining and UsingOsteoarthritis Initiative Data and ImagesJohn Lynch, PhDUpon completion of this session, participants should be able to:• describe the background, purpose, study design and data collectionprocedures of the Osteoarthritis Initiative• discuss types of investigation the database is designed to support• identify available public data• explain methods for obtaining and using Osteoarthritis Initiative data forresearchARHP SPECIAL SESSION12:30 - 2:15 pmNetworking ForumAll attendees are cordially invited to join one of the following networkingopportunities. Grab your lunch and join a group.Membership Recruitment Award PresentationGraduate Student Recognition Award PresentationPresidential WelcomeNadine T. James, RN, MSN, PhDProgram OverviewBenjamin J. Smith, PA-CINNOVATION THEATER12:30 - 1:15 pmInnovation Theater presentations will be listed in My ACR atwww.rheumatology.org/annual in early September.ACR MEET THE PROFESSOR SESSIONS12:45 - 2:15 pmFor more information, see page 60.ACR CLINICAL SYMPOSIUM1:00 - 2:00 pmC cP Difficult Raynaud’s Phenomena (Clinical Review)Speaker: Fredrick M. Wigley, MDUpon completion of this session, participants should be able to:• explain the evolving concepts of pathophysiology of Raynaud’s phenomenaand potential new avenues of therapeutic intervention• discuss evidence for pharmacologic, behavioral, and surgical approaches toRaynaud’s phenomena and its complicationsSUNDAYn o v e m b e r 6 , 2 0 1 1Visit My ACR at www.rheumatology.org/annual to plan your schedule and view up to date session, abstract and syllabi information.27

ACR/ARHP SCIENTIFIC SESSIONS• identify the appropriate use of these interventions and when simplesupportive treatment is warranted• gain insight into potential therapeutic interventions that are underinvestigation or in developmentACR PRACTICE ISSUES1:00 - 2:00 pmEd. Publishing in Peer-reviewed Medical JournalsHaving Your Article Reviewed for Publication in Arthritis Care & ResearchMarian T. Hannan, DSc, MPHHaving Your Article Reviewed for Publication in Journal of the AmericanMedical AssociationPhil Fontanarosa, MD, MBAHaving Your Article Reviewed for Publication in Journal of ClinicalInvestigationGary Koretsky, MD, PhDHaving Your Article Reviewed for Publication in Arthritis & RheumatismJoan M. Bathon, MDACR BASIC SCIENCE SYMPOSIUM2:30 - 4:00 pmr Tools for Studying Joint Tissue Changes in OsteoarthritisAdvances in Imaging of the Osteoarthritis JointGarry Gold, MDBiomarkers for Osteoarthritis: Are We Making Progress?Stefan Lohmander, MD, PhDOsteoarthritis Animal Models: What Have We Learned?Chris H. Little, MS, PA-CUpon completion of this session, participants should be able to:• describe advances in imaging, biomarkers, and animal models in theosteoarthritis field• list the biomarkers for osteoarthritis currently under investigation andrelate their ability to detect changes in tissues affected by osteoarthritis• recognize advances in joint tissue imaging technologies that have beenapplied to osteoarthritis• choose an appropriate animal model for osteoarthritis research and relatehow these models have advanced the osteoarthritis fieldSUNDAYn o v e m b e r 6 , 2 0 1 1Upon completion of this session, participants should be able to:• explain the journal’s objectives with respect to rheumatology• report what types of rheumatology articles are of interest to the journals• outline how to increase the likelihood of acceptance of an article forpublication in the respective journalACR SPECIAL SESSION1:00 - 2:00 pmEd. Medical Education: Year in ReviewSpeaker: Gerald Denton, MDUpon completion of this session, participants should be able to:• recognize the major research reports and scholarship in the field ofmedical education over the past year• translate results of educational research to educational programs• formulate ideas for educational research at their own institutionsACR STATE-OF-THE-ART LECTURE1:00 - 2:00 pmr MicroRNA in Epigenetic Regulation of Rheumatic InflammatoryDiseasesSpeaker: Steffen Gay, MDUpon completion of this session, participants should be able to:• appreciate basic principles of microRNA biology• define how particular microRNAs can increase or decrease transcriptexpression at a protein level• review emerging data in studies of rheumatoid synoviocytes and other celltypes involved in rheumatoid arthritisACR WORKSHOPS1:15 - 3:15 pmFor more information, see page 62.ACR/ARHP AFTERNOON SNACK BREAK2:00 - 3:00 pmComplimentary snacks will be provided in the Exhibit Hall.ACR CLINICAL SYMPOSIA2:30 - 4:00 pmC PSImpact of Environmental Health on AutoimmunityThe Environment and Autoimmune Diseases – Where We Stand in 2011Frederick W. Miller, MDThe Role of Gene X Environment Interactions in AutoimmunityJudith A. James, MD, PhDSmoking and Silica Exposure-Models for Exploring EnvironmentalTriggers of DiseaseGlinda S. Cooper, PhDUpon completion of this session, participants should be able to:• identify known and potential environmental triggers of autoimmunityand autoimmune diseases, including chemical factors, physical factors,biological agents and others• describe potential mechanisms for gene x environment interactions• summarize new technologies in exposure monitoringC PSLooking Ahead to Kinase Inhibition in Rheumatoid ArthritisWhich Kinase Pathways are Important in Rheumatoid Arthritis and HowDo We Decide What to Target?Mark C. Genovese, MDWhat Does the Data Inform Us About Safety and Efficacy of KinaseInhibitors?Michael E. Weinblatt, MDWhere Will These Agents Fit into Our Treatment Paradigm?Roy M. Fleischmann, MDUpon completion of this session, participants should be able to:• compare and contrast the mechanisms of action of the various kinaseinhibitors in late-stage clinical trials in rheumatoid arthritis• summarize the key data on safety and efficacy on these agents• formulate a plan for integrating these agents into existing managementstrategies for rheumatoid arthritis28

ACR/ARHP SCIENTIFIC SESSIONSACR SPECIAL SESSION2:30 - 4:00 pmP/C PSGreat Debate: Is Too Much Suppression of Turnover Badfor Bone?Speakers: Kenneth G. Saag, MD, MScDouglas C. Bauer, MDUpon completion of this session, participants should be able to:• define the evidence for and against use of bisphosphonates in osteoporosis• interpret the evidence for and against bisphosphonate use in light ofcurrent guidelines• utilize this improved understanding of the pros and cons ofbisphosphonates when discussing therapeutic options with patientsACR REF SPECIAL SESSION2:30 - 4:00 pmc/R REF “Within Our Reach”: Finding a Cure for RheumatoidArthritisMethotrexate and JUN Pathway Activation in Rheumatoid ArthritisNancy J. Olsen, MDAutoantibodies, Inflammation, and Cardiovascular Disease in Pre-ClinicalRheumatoid ArthritisJill Norris, MPH, PhDBiomarkers of Enhanced Cardiovascular Risk in Rheumatoid ArthritisJoan M. Bathon, MDUpon completion of this session, participants should be able to:• identify the role of methotrexate treatment in JUN pathway activation inthe pathogenesis of rheumatoid arthritis• describe the degree to which the immune system is dysregulated inrheumatoid arthritis patients even before there is recognizable synovitis• state what biochemical, genetic, and clinical features predict acceleratedcardiovascular disease in rheumatoid arthritisUpon completion of this session, participants should be able to:• describe concepts and terminology in the vocational intervention ofrheumatology patients• describe treatment options regarding a patient’s disability• identify different disability determinations and compensation systems• discuss how to properly complete the necessary paperwork• recognize legal issues as it relates to patients and health providersC Rehabilitation for the ClinicianReview of Common Rheumatologic Conditions Treated with PhysicalTherapy and Occupational TherapyVictoria L. Ruffing, RN and Donna K. Everix, MPA, BS, PTExercise and Rehabilitation for Common Rheumatologic ConditionsDonna K. Everix, MPA, BS, PTDemonstration and Practice of Exercises (Panel Discussion)Upon completion of this session, participants should be able to:• list common conditions encountered in rheumatology that could benefitfrom rehabilitation interventions• demonstrate specific exercises for common conditions encountered inrheumatology• identify “red flags” for urgent referral to rehabilitation or otherinterventionsINNOVATION THEATER2:30 - 3:15 pmInnovation Theater presentations will be listed in My ACR atwww.rheumatology.org/annual in early September.ACR/ARHP WORKSHOPS4:00 - 6:00 pmFor more information, see page 62.SUNDAYn o v e m b e r 6 , 2 0 1 1ACR AND ARHP CONCURRENT ABSTRACTSESSIONS2:30 - 4:00 pmAbstract PresentationsARHP CONCURRENT SESSIONS2:30 - 4:00 pmC Rheumatic Disease Update: Relapsing PolychondritisSpeaker: Jane Buckner, MDUpon completion of this session, participants should be able to:• describe the symptoms of relapsing polychondritis• describe how relapsing polychondritis is diagnosed• review the medication used to treat relapsing polychondritisBR C Disability: Clinical Facts, Legal Fictions, and Practice StrategiesClinical Facts: Vocational Rehabilitation and the Disability Spectrum forRheumatology ProfessionalsDonald Uslan, MA, MBA, LMHC, CRCLegal Fictions: Long-term DisabilityFrederick P. Langer, JDPractice Strategies: Disability in the Rheumatology PracticeRichard Jimenez, MDPanel DiscussionACR BASIC SCIENCE SYMPOSIUM4:30 - 6:00 pmR Crystals and Arthritis-Mechanisms of Inflammation and JointDestructionMechanisms for Urate Induced Joint InflammationRobert Terkeltaub, MDCalcium Crystals and Joint Tissue Destruction in OsteoarthritisAnn K. Rosenthal, MDThe Role of Anakinra in Chondrocalcinosis and Joint DiseaseCharlene Williams, PhDUpon completion of this session, participants should be able to:• define how the various types of crystals induce joint inflammation andjoint tissue destruction• describe how recent studies on urate crystals have led to a betterunderstanding of the role of the inflammasome in regulatinginflammation• relate calcium crystals in joint tissues to the pathogenesis of osteoarthritis• determine how mutations in the ank gene contribute to excessive jointtissue calcification and arthritisVisit My ACR at www.rheumatology.org/annual to plan your schedule and view up to date session, abstract and syllabi information.29

ACR/ARHP SCIENTIFIC SESSIONSSUNDAYn o v e m b e r 6 , 2 0 1 1MONDAYn o v e m b e r 7 , 2 0 1 1ACR CLINICAL SYMPOSIUM4:30 - 6:00 pmcP P/C PS Management of Antiphospholipid Syndrome: FromControversies to ConsensusPrimary ThromboprophylaxisDoruk Erkan, MDManagement of ThrombosisMunther A. Khamashta, MD, PhDManagement of PregnancyLisa R. Sammaritano, MDQuestion and AnswerUpon completion of this session, participants should be able to:• assess the risk of thrombosis in individuals that test positive forantiphospholipid antibodies• review the data on primary prevention in such individuals• identify the options for the management of thrombotic manifestations ofantiphospholipid syndrome• discuss the evidence and best data supporting treatment decisions inantiphospholipid syndrome• review the therapeutic options for the obstetric manifestations ofantiphospholipid syndrome• discuss the evidence and best data supporting treatment decisions inobstetric antiphospholipid syndromeACR MEET THE PROFESSOR SESSIONS4:30 - 6:00 pmFor more information, see page 60.ACR SPECIAL SESSIONS4:30 - 6:00 pmEd. ACR REF Special Session: Clinician Scholar Educator PresentationsIntroducing the Testimonial-Commentator Format to the MusculoskeletalCurriculum of Medical StudentsJames D. Katz, MDDevelopment of a Curriculum to Utilize Medical Resident Clinic forRheumatology EducationJames M. Ross, MDTeam-Learning Strategies in Rheumatology: Fostering Accountability,Reflective Learning and Critical ThinkingKarina Marianne D. Torralba, MDACR AND ARHP CONCURRENT ABSTRACTSESSIONS4:30 – 6:00 pmAbstract PresentationsARHP CONCURRENT SESSIONS4:30 - 6:00 pmC Axial Spondylarthritis: New ConceptsSpeaker: Muhammad Asim Khan, MDUpon completion of this session, participants should be able to:• differentiate inflammatory back pain from mechanical back pain• discuss how to diagnose axial spondylarthritis in the absence of sacroiliitis• identify the “spondylarthritis” features in the definition of axialspondyloarthritisc/R PSDeconstructing the Randomized Controlled Trial: Assessingthe Study Quality of Level One Non-drug StudiesSpeakers: Susan L. Murphy, ScD, OTRNancy A. Baker, ScD, MPH, OTR/LUpon completion of this session, participants should be able to:• discuss quality issues of non-drug randomized controlled trials• describe the elements of randomized controlled trials that contribute tohigher research quality• recognize and explain the Consolidated Standards of Reporting Trialsguidelines for reporting results from non-drug randomized controlled trialsc PSIatrogenic Misadventures in Osteoporosis TreatmentSpeaker: Susan B. Broy, MDUpon completion of this session, participants should be able to:• discuss risks associate with therapies approved to treat osteoporosis• describe the incidence and risks of atypical femur fractures andosteonecrosis of the jaw in patients being treated for osteoporosis• discuss current recommendations for calcium and vitamin Dsupplementation and review studies that suggest too much of thesenutrients may be harmfulINDUSTRY ROUNDTABLE-SUPPORTED SYMPOSIA6:30 - 9:30 pmThese symposia are both CME-accredited and non-CME company-directed programs.For CME-accredited symposia, the sponsoring organization is responsible for planningand providing CME credit. All non-CME programs are wholly sponsored andsupported by commercial entities.30Upon completion of this session, participants should be able to:• discuss novel approaches to curriculum development for medical studentsand residents in the musculoskeletal and rheumatic diseases• discuss new approaches to teaching in the rheumatic and musculoskeletaldiseases• review important areas of overlap in medical education between geriatricmedicine and rheumatology and the impact of this education on qualityof care• summarize the unique and important roles of the clinician scholareducator in medical education and trainingLegislative Update from Capitol HillThis session is not eligible for CME credit.Upon completion of this session, participants should be able to:• discuss current legislative initiatives in Congress affecting rheumatology• outline the Administration’s role in developing health policy• recognize the value of grassroots advocacy in communicating with CongressMONDAY, NOVEMBER 7, 2011ACR IMMUNOLOGY UPDATES FOR THECLINICIANS7:30 - 8:30 amc/R T Cell Regulation and Autoimmune Pathogenesis: Th1, Th2, Th17and T RegsSpeaker: Jane Hoyt Buckner, MDUpon completion of this session, participants should be able to:• explain basic principles of T cell biology and selection of antigen specificresponses• define how the local cytokine milieu can affect biased T cell responses• review emerging data in mouse models and clinical studies how certain Tcell responses can drive a disease process, while other T cell responses cansuppress the disease

ACR/ARHP SCIENTIFIC SESSIONSACR SPECIAL SESSION7:30 - 8:30 amc cP PSClinicopathologic Conference: A 40 Year-Old Male withDyspnea on ExertionCase PresentationsSpeakers: Nadera J. Sweiss, MDAmit Patel, PharmDAliya Husain, MDJohn F. Beshai, MDUpon completion of this session, participants should be able to:• identify some cardiopulmonary manifestations of select systemic disorders• describe the limitations of the common laboratory and radiographictesting in making a clinical diagnosis• discuss the clinical, pathologic diagnosis, treatment and follow up of thecase presentedACR STATE-OF-THE-ART LECTURE7:30 - 8:30 amR Moving Forward in the Genome Wide Association Studies EraThe Power of Next-Generation DNA Sequencing Approaches forIdentifying Causal Genetic Variation in Autoimmune DiseaseDavid B. Goldstein, PhDUpon completion of this session, participants should be able to:• describe the gap between the success of genome wide association studiesin identifying genetic loci for autoimmune disease and the proportion ofheritability that is explained by currently identified loci• summarize current theories about factors that may explain this “missingheritability”• explain features of “next-generation” DNA sequencing approaches thathave made sequencing a feasible approach for identifying causal geneticvariationARHP CONCURRENT SESSIONS7:30 - 8:30 amC Behave Yourself! Practical Application of Cognitive BehavioralTheories to Motivate Change in Patients with ArthritisThis session will include skills demonstration and coaching for participants.Speakers: Susan J. Bartlett, PhDSarah Hewlett, PhD, MA, RNUpon completion of this session, participants should be able to:• review readiness to change, motivational interviewing and guideddiscovery theories• apply motivational interviewing, guided discovery, and goal-settingtechniques in a non-judgmental and guided environmentBR R ICD Coding - Crash Course for ResearchersSpeaker: Michael M. Ward, MDUpon completion of this session, participants should be able to:• recognize analytic issues encountered when utilizing ICD codes foradministrative database research• describe features related to the ICD-9 to ICD-10 transition and how theseimpact research spanning both systems• apply these concepts to rheumatic disease researchc/R New and Noteworthy: Nursing, Pharmacy and PedorthicsYear in Review for Nursing and Advance Practice NursingBasia Belza, PhD, RNPharmaceutical Advances in Pharmacologic Treatments in RheumaticDiseasesKamala M. Nola, PharmD, MSInnovative Footware/Footcare Can Make a Big Difference in So ManyWaysDennis J. Janisse, CPedUpon completion of this session, participants should be able to:• summarize research advances in rheumatologic nursing within the past12 months• describe recent advances in pharmacologic treatments for rheumaticdiseases• review recent advances in pedorthics and application of this newinformation to rheumatology practice• describe the significance of these advances for practitioners, educators andresearchersC PMSleep Disturbance in FibromyalgiaSpeaker: Robert M. Bennett, MDUpon completion of this session, participants should be able to:• review appropriate investigations in patients with fibromyalgia who aresuspected to have a major sleep disturbance• discuss common sleep abnormalities seen in fibromyalgia patients• describe management options in these patientsACR MEET THE PROFESSOR SESSIONS7:45 - 9:15 amFor more information, see page 60.ACR/ARHP WORKSHOPS7:45 - 9:45 amFor more information, see page 62.ACR MEDICAL ASPECTS OF RHEUMATICDISEASES9:00 - 10:00 amcP P/C Anemia of Inflammatory DiseaseSpeaker: Brady L. Stein, MDUpon completion of this session, participants should be able to:• discuss mechanisms in the etiology of anemia of inflammatory disease• recognize the guidelines for the treatment of anemia of inflammatorydisease• develop therapeutic strategies for the management of anemia in patientsfor which treatment of the underlying chronic disease is limitedACR PRACTICE ISSUES9:00 - 10:00 amBR C cP RAC & Roll – How to Perform Complex Chart AuditsPractical Auditing Guidelines and Procedures for Physician PracticesMelesia Tillman, CPC, CRHC, CHAMONDAYn o v e m b e r 7 , 2 0 1 1Visit My ACR at www.rheumatology.org/annual to plan your schedule and view up to date session, abstract and syllabi information.31

ACR/ARHP SCIENTIFIC SESSIONSMONDAYn o v e m b e r 7 , 2 0 1 1Upon completion of this session, participants should be able to:• perform complex audits from actual rheumatology charts• identify key risk areas that are under the microscope of the Recovery AuditContractor• recognize how to prepare and survive a Recovery Audit Contractor auditACR STATE-OF-THE-ART LECTURES9:00 - 10:00 amC PSCervical Spine Surgeries in Rheumatic Diseases: 2011 UpdateCervical Spine Surgery in the Rheumatic Disease PatientHoward An, MDUpon completion of this session, participants should be able to:• order the appropriate imaging studies in the rheumatologic patient withcervical spine disease• review the indications for cervical spine surgery in these patients• discuss the current surgical interventions for the rheumatologic patientwith cervical spine disease• recognize challenges in cervical spine surgeries in the rheumatic diseasepatientR Innate ImmunitySpeaker: Dan Stetson, PhDUpon completion of this session, participants should be able to:• evaluate the main mechanisms by which inflammatory and immuneresponses are initiated• explain how these mechanisms contribute to immune dysregulation andautoimmune tissue damage• describe how novel innate immune therapies may offer new prospects forclinical benefitACR/ARHP POSTER SESSION B AND POSTERTOURS9:00 am - 6:00 pmPoster presenters will be available from 9:00 - 11:00 AM. Poster tours will be held9:00 - 9:45 AM and 10:15 - 11:00 AM. Morning snacks will be available from 9:00- 10:30 AM.ACR REF SPECIAL SESSION9:00 - 10:00 amr ACR REF Memorial Lectureship: From Shulman’s Syndrometo Nephrogenic Systemic Fibrosis: Exogenous Factorsand Systemic Fibrosing DisordersSpeaker: Sergio A. Jimenez, MDThe 2011 REF Memorial Lectureship is in honor of Lawrence E. Shulman, MD.P/C Preparing for Transition from Day One of Diagnosis to Adult CareIntroductionKatherine A.B. Marzan, MDOverview of Adult Providers Expectations of Pediatric Patients AttendingClinicElizabeth C. Ortiz, MDThe “Toolbox” Needed for the Journey from Pediatrics to Adult CareSandra J. Watcher, BSNPanel DiscussionUpon completion of this session, participants should be able to:• define what is expected by adult providers• discuss methods in which adult providers can ease the transition duringinitial appointments• identify key aspects to prepare pediatric patients from the first day ofdiagnosis through transition• review the tools that pediatric providers can provide their patients andtheir familiesC Rheumatic Disease Update: Musculoskeletal Manifestiations ofHuman Immunodeficiency VirusSpeaker: Ajay Wanchu, MDUpon completion of this session, participants should be able to:• discuss the incidence and prevalence of rheumatic disorders in patientswith human immunodeficiency virus infection before and after highlyactive antiretroviral therapy• review antirheumatic therapies that can be used in humanimmunodeficiency virus-positive individuals with and without low CD4 Tcell counts• develop a treatment plan for an individual with human immunodeficiencyvirus related arthritisc/R To P or Not to P? Knowing When the P-value is Less Than UsefulThe P-value and Statistical SignificanceMichael P. LaValley, PhDTime to Beat Up the P-valueDaniel K. White, PT, ScDUpon completion of this session, participants should be able to:• define the p-value, its statistical significance and identify situations whereit is appropriately used• describe situations where the standard p-value is of limited use, e.g., inpost-hoc analyses, multiple comparisons, stepwise regression, and indescribing the strength of an effect• identify alternative approaches to the p-value, e.g., confidence intervals,exploratory analyses, causal models and diagrams, and effect size measures• discuss measures of meaningful changeARHP CONCURRENT SESSIONS9:00 - 10:00 amC Antimalarials for Rheumatic Disorders: Historical Perspectives,Clinical Insights and Future DirectionsSpeaker: Daniel J. Wallace, MDUpon completion of this session, participants should be able to:• review the history of the use of antimalarials• summarize the clinical trials investigating antimalarial medications• identify the potential side effects of antimalarials• outline future directions for the use of this class of medicationsEXHIBITS AND REPLAY CAFÉ10:00 am - 7:00 pmACR WORKSHOPS10:30 am - 12:30 pmFor more information, see page 62.INNOVATION THEATER10:30 - 11:15 amInnovation Theater presentations will be listed in My ACR atwww.rheumatology.org/annual in early September.32

ACR/ARHP SCIENTIFIC SESSIONSARHP GENERAL SESSION II10:30 - 11:30 amcP ARHP Distinguished LecturerSpeaker: Anthony D. Woolf, MBBSUpon completion of this session, participants should be able to:• state the achievements of the United States Bone and Joint Initiative• discuss the burden of musculoskeletal diseases in developing as well asdeveloped countries• describe strategies that can be undertaken at a national level to reduce theburden of musculoskeletal disordersACR CLINICAL SYMPOSIA11:00 am - 12:30 pmp Juvenile Idiopathic Arthritis: Clinical Heterogeneity and theGenomeHistorical Overview of Juvenile Idiopathic Arthritis Classification andGeneticsDavid N. Glass, MDJuvenile Idiopathic Arthritis: The Clinical PhenotypesAlberto Martini, MDGenotype-Phenotype Correlations in Juvenile Idiopathic ArthritisSampath Prahalad, MD, MScGene Expression in Juvenile Idiopathic Arthritis and the ClinicalPhenotypesLucy R. Wedderburn, MD, PhDUpon completion of this session, participants should be able to:• assess phenotypic subgroups within juvenile idiopathic arthritis• review recent progress toward understanding genotype-phenotypecorrelations within juvenile idiopathic arthritis• discuss the significance of recent gene expression studies for thecategorization of juvenile idiopathic arthritisC PSTreatment of Lupus NephritisClinical Trials in Lupus Nephritis: The Challenges and the Results– Mycophenolate, Rituximab, Abatacept, Azathioprine, CalcineurinInhibitorsJoan T. Merrill, MDThe 2011 ACR Guidelines for Management of Lupus NephritisBevra H. Hahn, MDLupus Nephritis: The Future: Prevention of Renal Failure, Biomarkers,and New Products in Clinical TrialsBrad H. Rovin, MDUpon completion of this session, participants should be able to:• explain the results of large clinical trials in patients with lupus nephritis• cite the 2011 ACR lupus nephritis guidelines• describe the new developments in biomarkers of disease activity,prevention of renal failure, and new therapies currently in clinical trialsc/R ACR PLENARY SESSION II: DISCOVERY 201111:00 am - 12:30 pmACR Abstract Presentation and CommentariesACR PRACTICE ISSUES11:00 am - 12:30 pmcP The Road to Meaningful Use and Beyond: A Simple Overview of aComplex TopicWhat is Meaningful Use and What Does It Mean for Me?Speaker to be announcedDeveloping a Solid Plan for Your Electronic Practice: How Do I Get toMeaningful Use?Robert W. Warren, MD, PhD, MPHAn Electronic Health Record Isn’t Enough: Information Exchange forMeaningful UseLaura Zaremba, BA, MAUpon completion of this session, participants should be able to:• describe the rationale behind the Centers for Medicare and MedicaidServices electronic health records incentive program (meaningful use) andthe requirements and criteria for incentive funding• identify the electronic health records incentive program’s impact on thepractice of rheumatology, including how operations must be modified tosuccessfully achieve meaningful use• describe the functionality objective and clinical quality measures mostrelevant to rheumatology providers• identify the value of electronic health records system certification andmeaningful use standards as a path to achieving interoperability of healthinformation and data exchange• discuss the benefits of health information technology beyond electronichealth records• describe the functionality objectives and clinical quality measures expectedfor future stages of the electronic health records incentive programACR SPECIAL SESSION11:00 am - 12:30 pmC cP Curbside Consults - Ask the ProfessorsScleroderma: Challenges in Clinical PracticeLaura K. Hummers, MD, ScMDifficult Myopathy: When Your Exam and Labwork Don’t EquateRobert L. Wortmann, MDThe Challenges of Fertility and Pregnancy in Patients with LupusMichael D. Lockshin, MDUpon completion of this session, participants should be able to:• compare their personal management approaches to selected clinicalproblems with those of the presenters• describe therapeutic choices and management options for several commonbut difficult complications of scleroderma• develop an approach to evaluating and managing patients presenting withasymptomatic elevation in muscle enzymes• appraise the potential impact on fertility and pregnancy of varioustreatments for systemic lupus erythematosusARHP SPECIAL SESSIONnoon - 1:30 pmNetworking at NoonSit down with you colleagues, enjoy a light lunch and participate in an opendiscussion on various pre-selected research, practice and clinical topics. Eachroundtable discussion will be facilitated by a rheumatology expert. All ARHPattendees are welcome to participate in this event. For a listing of roundtabletopics, visit My ACR at ww.rheumatology.org/annual.MONDAYn o v e m b e r 7 , 2 0 1 1Visit My ACR at www.rheumatology.org/annual to plan your schedule and view up to date session, abstract and syllabi information.33

ACR/ARHP SCIENTIFIC SESSIONSINNOVATION THEATER12:30 - 1:15 pmInnovation Theater presentations will be listed in My ACR atwww.rheumatology.org/annual in early September.ACR MEET THE PROFESSOR SESSIONS12:45 - 2:15 pmFor more information, see page 60.ACR SPECIAL SESSIONACR STATE-OF-THE-ART LECTURE1:00 - 2:00 pmC PSBiomarkers in Systemic Lupus Erythematosus: Where Do WeStand?Speaker: Jill P. Buyon, MDUpon completion of this session, participants should be able to:• explain what makes a good biomarker• describe the current list of systemic lupus erythematosus biomarkers underinvestigation• outline the potential clinical application of the current biomarkersMONDAYn o v e m b e r 7 , 2 0 1 112:45 - 2:15 pmBR Ed. F Contract Negotiations for PhysiciansContract Negotiations for Academics: How to Optimize Your AcademicLetter of Offer/ContractRichard M. Pope, MDContract Negotiations for Industry: How to Optimize Your IndustrialLetter of Offer/ContractGregory J. Dennis, MDContract Negotiations for Private Practice: How to Optimize a PrivatePractice or Hospital Practice ContractHerbert Baraf, MDContract Negotiations and the Legal Ramifications of the Contract: Howto Optimize the Contract and Protect YourselfJoan M. Roediger, JD, LLMUpon completion of this session, participants should be able to:• explain the value of legal advice prior to signing a contract and the legalramifications of the contract• identify a fair private practice or hospital practice contract and how tosuccessfully modify it to correspond with their individual needs• negotiate a fair academic or industrial letter of offer/contractACR CLINICAL SYMPOSIUM1:00 - 2:00 pmcP P/C Did You Brush Your Teeth Today? (Clinical Review)Speaker: Michele Ravenel, DMDUpon completion of this session, participants should be able to:• outline the pathophysiologic mechanisms by which periodontal diseaseinterplays with autoimmune disease• recognize what can be done to improve periodontal health in patientswith established autoimmune diseases, including scleroderma, Sjögren’ssyndrome and rheumatoid arthritis• outline practical advice for patients on the oral complications ofautoimmune disease and therapiesACR SPECIAL SESSION1:00 - 2:00 pmC PS2011 Updated ACR Rheumatoid Arthritis GuidelinesSpeakers: Jasvinder Singh, MD, MPHKenneth G. Saag, MD, MScDaniel E. Furst, MDUpon completion of this session, participants should be able to:• describe the recommended treatment approach for patients withrheumatoid arthritis• review the recommendations for indications of biologic and non-biologicdisease-modifying agents in the treatment of rheumatoid arthritis• review the recommendations for tuberculosis screening and vaccination inpatients with rheumatoid arthritisACR WORKSHOPS1:15 - 3:15 pmFor more information, see page 62.ACR BASIC SCIENCE SYMPOSIA2:30 - 4:00 pmr Fibrosis: Novel ParadigmsCellular Senescence and FibrosisLester F. Lau, PhDMechano-Signal TransductionBoris Hinz, PhDInnate Immune Signaling and FibrosisCory M. Hogaboam, PhDUpon completion of this session, participants should be able to:• describe the biology and impact of fibrosis• evaluate new concepts in fibroblast biology• recommend novel targets for therapy of fibrosisr Rheumatoid Arthritis: Where Does It Begin?Where is the Inflammation: The Synovium and Lymph Nodes in PrerheumatoidArthritisDanielle Marie Gerlag, MD, PhDMolecular Links between Periodontitis and Autoimmunity in RheumatoidArthritisPatrick Venables, MDThe Lung as a Site of Initiation of Rheumatoid Arthritis-relatedAutoimmunityKevin D. Deane, MDUpon completion of this session, participants should be able to:• define the role and supportive evidence for pulmonary and periodontaldisease in early rheumatoid arthritis• appraise the role of inflammation in different tissues in early rheumatoidarthritis• determine situations where interventions in non-synovial organs mightlead to prevention of rheumatoid arthritis• identify targets for intervention to prevent development of rheumatoidarthritis in those at riskACR CLINICAL SYMPOSIUM2:30 - 4:00 pmp Advances in Polyarticular Juvenile Idiopathic ArthritisToward Remission in Polyarticular Juvenile Idiopathic ArthritisCarol A. Wallace, MD34

ACR/ARHP SCIENTIFIC SESSIONSImmune Tolerance in the Treatment of Polyarticular Juvenile IdiopathicArthritisSalvatore Albani, MD, PhDNewer Rheumatoid Arthritis Treatment StrategiesLucy R. Wedderburn, MD, PhDUpon completion of this session, participants should be able to:• describe the evidence supporting early aggressive treatment of polyarticularjuvenile idiopathic arthritis• review the rationale for designing more aggressive therapies in juvenileidiopathic arthritis• identify the role immune tolerance plays in therapeutic response inpolyarticular juvenile idiopathic arthritis• explain how functional genomics can be used to reflect immunologicchange in response to therapy, and predict which treatments may bemost effective in individual patients with polyarticular juvenile idiopathicarthritisACR SPECIAL SESSION2:30 - 4:00 pmcP P/C PS Thieves’ Market: Show Me Your Best CasesImage CompetitionCase PresentationsUpon completion of this session, participants should be able to:• describe unique and challenging diagnostic dilemmas• discuss the differential diagnosis• review methods used to identify the underlying diagnosis• develop a treatment plan specific to the underlying diagnosisACR REF SPECIAL SESSION2:30 - 4:00 pmc/R ACR REF Edmond L. Dubois, MD, Memorial LectureshipLectureship recipient will be selected based on an accepted abstract related to systemiclupus erythematosus.ACR AND ARHP CONCURRENT ABSTRACTSESSIONS2:30 - 4:00 pmAbstract PresentationsARHP CONCURRENT SESSIONS2:30 - 4:00 pmC PMDebate: Joints for Joints: Medical Marijuana is Useful forTreating Rheumatic DiseaseConStuart L. Silverman, MDProArthur Kavanaugh, MDUpon completion of this session, participants should be able to:• discuss the immunomodulatory properties of cannabinoids• review the pros and cons of legalizing medical marijuana as a treatmentmodality• list the adverse effects of medical marijuanaC PMFoot Structure, Footwear and Foot Pain – TranslatingEvidence into PracticeBiomechanical Mechanisms Contributing to Foot PainHoward J. Hillstrom, PhDFootwear and Foot Pain: Evidence from Population-based StudiesMarian T. Hannan, DSc, MPHDesigning Strategies to Prevent and Treat Foot PainSmita Rao, PT, PhDUpon completion of this session, participants should be able to:• describe mechanisms by which foot structure and footwear contribute tofoot pain• evaluate recent evidence investigating factors contributing to foot pain• design and implement strategies to evaluate, prevent and treat foot painC Rheumatic Disease Update: Paraneoplastic Rheumatic DisordersSpeaker: Yusuf Yazici, MDUpon completion of this session, participants should be able to:• discuss the risk of occult malignancy in patients with dermatomyositis,remitting seronegative symmetric synovitis with pitting edema, andpolymyalgia rheumatica• develop a plan for investigating patients with rheumatic diseases that arethought to be paraneoplastic• describe the clinical features that help distinguish paraneoplastic fromidiopathic rheumatic disordersINNOVATION THEATER2:30 - 3:15 pmInnovation Theater presentations will be listed in My ACR atwww.rheumatology.org/annual in early September.ACR/ARHP WORKSHOPS4:00 - 6:00 pmFor more information, see page 62.ACR CLINICAL SYMPOSIA4:30 - 6:00 pmC cP Difficult to Treat Systemic Lupus Erythematosus: Case StudiesRefractory Mucocutaneous DiseaseVictoria P. Werth, MDWhen Hydroxychloroquine is Not EnoughDavid A. Isenberg, MDThe Value of Biologic Registries: Where Are We in Systemic LupusErythematosus?Ronald Van Vollenhoven, MD, PhDUpon completion of this session, participants should be able to:• describe management strategies for hard to treat mucocutaneous disease• review the evidence for immunosuppressive therapy beyondhydroxychloroquine• discuss approaches to severe organ threatening lupusC Heart Disease and Rheumatoid ArthritisRisk Factors for Cardiac Complications in Rheumatoid Arthritis: WhatShould the Clinician Be Looking For?Joan M. Bathon, MDMONDAYn o v e m b e r 7 , 2 0 1 1Visit My ACR at www.rheumatology.org/annual to plan your schedule and view up to date session, abstract and syllabi information.35

ACR/ARHP SCIENTIFIC SESSIONSHow to Improve Cardiac Health in Rheumatoid Arthritis Patients: Targetsfor Primary and Secondary PreventionJon T. Giles, MD, MPHCardioprotective Effects of Disease-modifying Anti-rheumatic DrugsWilliam G. Dixon, MRCP, PhDUsing the Clinical and Translational Science Award in Your RheumatologyResearchGary S. Firestein, MDHow I Used the Clinical and Translational Science Award in My ResearchTim Bongartz, MD and Megan E. B. Clowse, MD, MPHMONDAYn o v e m b e r 7 , 2 0 1 1Upon completion of this session, participants should be able to:• describe the risk factors for heart disease in rheumatoid arthritis• explain strategies for improving cardiac health in rheumatoid arthritispatients• recognize cardio-protective effects of disease-modifying anti-rheumaticdrugsP/C PSTotal Hip and Knee Replacements 2011: An Update forRheumatologistsThe Changing Demographics of End-Stage Hip and Knee OsteoarthritisJoanne M. Jordan, MD, MPHDoc, What Should I Do About My Knee?: Who Should RheumatologistsBe Referring for ArthroplastyLisa A. Mandl, MD, MPHArthroplasty Outcomes 2011Jeffrey N. Katz, MD, MScUpon completion of this session, participants should be able to:• describe how the population with end-stage osteoarthritis is changing• cite evidence-based reasons for appropriate referrals for total jointreplacement• explain the short and long-term outcomes in total joint replacementACR MEET THE PROFESSOR SESSIONS4:30 - 6:00 pmFor more information, see page 60.ACR SPECIAL SESSIONS4:30 - 6:00 pmP/C ILAR Global Health ProjectInternational League of Associations for Rheumatology: Past, Present andFutureMark Andrejeski, Paul Davis, MD and Luis R. Espinoza, MDThe National Institutes of Health National Center for Research Resources:Who We Are and How We Can Help YouAnthony Hayward, MD, PhDPanel DiscussionUpon completion of this session, participants should be able to:• explain the nature of Clinical and Translational Science Award centersand how they may be used to support research efforts through subjectenrollment, specimen collection, laboratory analysis, and biostatisticalservices• identify funding mechanisms available to early career investigators throughClinical and Translational Science Award centers• describe non- Clinical and Translational Science Award mechanismsfor research support through the National Institutes of Health NationalCenter for Research Resourcesc/R The Earliest Phases of Rheumatoid Arthritis: Update on Americanand European InitiativesWhat Do Longitudinal Cohort Studies Tell Us About Development ofRheumatoid Arthritis Among High Risk Populations?Elizabeth Wood Karlson, MDFrom Studies of Pre-clinical Rheumatoid Arthritis Towards Prevention ofthe DiseasePaul P. Tak, MD, PhDPanel DiscussionV. Michael Holers, MD; Lars Klareskog, MD, PhD; Paul P. Tak, MD, PhD;Hani S. El-Gabalawy, MD and Elizabeth Wood Karlson, MDUpon completion of this session, participants should be able to:• define the different stages in the development of rheumatoid arthritis,with focus on description and definition of the preclinical phases ofdisease• describe the interplay of family history, genes, and environmental factorsin the development of autoimmunity• review data on the biologic processes in preclinical autoimmunity• review the outline of a clinical trial in preclinical rheumatoid arthritisInternational League of Associations for Rheumatology COPCORDRepositoryArvind A. Chopra, MDReinstatement of Clinical Anatomy as a Basic Knowledge for theRheumatologist in Latin AmericaPablo Villaseor-Ovies, MDUpon completion of this session, participants should be able to:• describe the rationale for International League of Associations forRheumatology’s reorganization• state International League of Associations for Rheumatology’s mission andgoals• explain the funding opportunities for programs that lead to progress inthe practice and education of rheumatology in countries where there is anexceptional needc/R Leveraging Existing Resources for Your Research: Clinical andTranslational Science Award Centers and AlternativesIntroduction to the Clinical and Translational Science AwardBruce N. Cronstein, MDACR REF SPECIAL SESSION4:30 - 6:00 pmc/R ACR REF Marshall J. Schiff, MD, MemorialLectureship: Multicenter Orthopaedic Outcomes Network -A Prospective Longitudinal Cohort of ACL ReconstructionOutcomesSpeaker: Kurt P. Spindler, MDUpon completion of this session, participants should be able to:• describe strengths and weaknesses of prospective longitudinal cohortstudies• learn modifiable predictors of clinically relevant anterior cruciate ligamentoutcomes• explain the rationale behind the design and development of theMulticenter Orthopaedic Outcomes Network36

ACR/ARHP SCIENTIFIC SESSIONSACR AND ARHP CONCURRENT ABSTRACTSESSIONS4:30 - 6:00 pmAbstract PresentationsARHP CONCURRENT SESSIONS4:30 - 6:00 pmC Disease Modifying Osteoarthritis Drugs, Glucosamine/Chondroitin and Non-pharmacologic Treatment of OsteoarthritisSpeakers: Carol A. Oatis, PT, PhDDavid T. Felson, MD, MPHMarc C. Hochberg, MD, MPHUpon completion of this session, participants should be able to:• list multiple treatment methodologies for osteoarthritis• describe current research and recommendations for treatment ofosteoarthritis• explain benefits and concerns for each type of osteoarthritis treatmentp Improving Adherence in the Pediatric Patient (Pediatrics)Impact of Non-adherence from the Medical PerspectiveRhina Castillo, MDImpact of Non-adherence from a Physical and Occupational TherapyPerspectiveTalitha Cox, MA, OTR/L and Jill R. Blitz, PTImpact of Non-adherence from a Nursing PerspectiveSandra J. Watcher, BSNImpact of Non-adherence from a Social Work PerspectiveAlana Epstein, MSWPanel DiscussionUpon completion of this session, participants should be able to:• describe barriers to learning and adherence• examine methods to overcome the barriers to improve learning andadherence• discuss age appropriate methods to educate children and adolescentsregarding rheumatic diseases and medications• identify available age appropriate materials and resources for patient,family and educators to use• discuss perspectives and recommendations from other centers using aninteractive open panelc/R Theories on Sex Disparities in Autoimmune Disease: FromEstrogen to the X ChromosomeSpeakers: Cherie L. Butts, PhDBruce C. Richardson, MD, PhDAmr H. Sawalha, MDUpon completion of this session, participants should be able to:• describe and contrast theories underlying the increased risk ofautoimmune disease among females• cite evidence for contemporary hypotheses related to excess risk amongfemales• discuss currently proposed mechanisms of autoimmunity in malesACR WINE AND CHEESE RECEPTION5:00 - 7:00 pmAll registered attendees are welcome to attend the Wine and Cheese Reception in theExhibit Hall.ACR STUDY GROUPS6:45 - 8:00 pmView complete session details in My ACR at www.rheumatology.org/annual. StudyGroups are not eligible for CME credit.ACR-EULAR ExchangeAntiphospholipid Study GroupAutoantibodies in Diagnosis and Follow up of Rheumatic DiseasesCapillaroscopy in Rheumatic DiseasesChildhood VasculitisGeriatric RheumatologyHypermobility IInterstitial Lung DiseaseJuvenile Arthritis WorkshopMusculoskeletal UltrasoundPatient Perspective on Outcomes: Methods of Ensuring the PatientPerspective is Included in Patient Reported Outcome InstrumentsPediatric Rheumatology ImagingPolymyalgia RheumaticaSpondylarthritisTUESDAY, NOVEMBER 8, 2011REF 5K RUN/WALK6:00 - 8:00 amJoin us for the 2011 REF 5K Run/Walk and enjoy the Windy City while helpingthe ACR Research and Education Foundation raise money to ensure thefuture of rheumatology. The graceful Chicago skyline, the shimmering watersof Lake Michigan and iconic structures like Soldier Field inspire runners everyday in the Midwest’s largest running community.Register online for only $25 as you register for the annual meeting, or visitwww.rheumatology.org/REF. On-site registration is $30 and subject to spaceavailability. Complimentary shuttle service to and from the run course is provided.All participants will receive an official REF 5K Run/Walk T-shirt.ACR MEDICAL ASPECTS OF RHEUMATICDISEASES7:30 - 8:30 amC cP Celiac Disease: Immunopathogenesis and Clinical SpectrumPotentialSpeaker: Joseph A. Murray, MDUpon completion of this session, participants should be able to:• identify the epidemiology of celiac disease• describe the pathophysiology of celiac disease and factors leading to diseasevariability• recognize the clinical spectrum of presentations of celiac disease• determine when and how to evaluate patients for celiac diseaseMONDAYn o v e m b e r 7 , 2 0 1 1TUESDAYn o v e m b e r 8 , 2 0 1 1Visit My ACR at www.rheumatology.org/annual to plan your schedule and view up to date session, abstract and syllabi information.37

ACR/ARHP SCIENTIFIC SESSIONSTUESDAYn o v e m b e r 8 , 2 0 1 1ACR SPECIAL SESSION7:30 - 9:00 amBR Ed. Gender Issues in the Rheumatology WorkforceUpdate on Gender Issues in Rheumatology: Analysis of 2011 ACR DataAbby Goulder Abelson, MDNational Trends of Women in Academic MedicineSheila A. Dugan, MDA Call to Action: What Can the ACR Do to Support Women in theRheumatology Workforce?Leslie J. Crofford, MDUpon completion of this session, participants should be able to:• review the data on current workforce issues related to gender inrheumatology• identify barriers women face in professional advancement• identify successful innovations that support women’s advancement intoleadership• discuss barriers to success in research careers• define strategies to enhance the role of women in academic medicineACR STATE-OF-THE-ART LECTURES7:30 - 8:30 amR Complimentary Roles for Complement in the Rheumatic DiseasesSpeaker: John D. Lambris, PhDUpon completion of this session, participants should be able to:• appreciate basic principles of complement biology• define how particular complement factors can enhance immune defensesfrom infection, or contribute to host homeostasis• review emerging data on unexpected roles of complement, and aberrantpathways in the immune pathogenesis of inflammatory diseasesR New Insights into Bone RemodelingSpeaker: Dallas Jones, PhDUpon completion of this session, participants should be able to:• discuss the basic anatomy and physiology of bone• review recent progress in the understanding of bone formation anddegradation• evaluate potential novel therapeutic targets for bone disease in arthritisand osteoporosisc/R cP PS Omega-3 Fatty Acids in Inflammation and CardiovascularHealthN-3 Fatty Acids, Inflammation, and Cardiovascular DiseaseArtemis P. Simopoulos, MDN-3 Fatty Acids in Rheumatic Diseases and the Intersection withCardiovascular MorbidityJoel M. Kremer, MDUpon completion of this session, participants should be able to:• describe the scientific basis for the antiinflammatory, immunomodulatoryand clinical effects of N-3 fatty acids in health and disease• discuss the impact of N-3 fatty acids in rheumatoid arthritis• discuss the impact of N-3 fatty acids on cardiovascular morbidity andmortalityARHP CONCURRENT SESSIONS7:30 - 8:30 amp An Update in the Diagnosis and Management of JuvenileDermatomyositisDiagnosis and Assessment of Juvenile DermatomyositisAngelo Ravelli, MDMedical Management of Juvenile DermatomyositisClarissa Pilkington, MDPhysical Management of Juvenile DermatomyositisElaine Haggart, BSc, (Hons), PhysiotherapyUpon completion of this session, participants should be able to:• assess and diagnose juvenile dermatomyositis• explain the core outcome criteria that are being developed for monitoringjuvenile dermatomyositis• review the latest approaches in medical management of juveniledermatomyositis in children• explain the physical management and the effectiveness of exercise in themanagement of juvenile dermatomyositisC Cognitive Function in Systemic Lupus ErythematosusSpeaker: Robin L. Brey, MDUpon completion of this session, participants should be able to:• describe cognitive function in patients with systemic lupus erythematosus• define the role of depression in the cognitive dysfunction of patients withsystemic lupus erythematosus• review the proper cognitive evaluation of a patient with systemic lupuserythematosus• identify potential treatment options for the various scenarios of cognitivedysfunction in patients with systemic lupus erythematosus• outline future research in the area of cognitive function in patients withsystemic lupus erythematosusc/R Mechanical Factors in Knee Osteoarthritis: A Plausible Road toRichesRole of Mechanical Factors in Disease Development, Disease Progression,and Function Decline in Knee OsteoarthritisLeena Sharma, MDEmerging Prevention and Intervention Strategies for Knee Osteoarthritisthat Target Mechanical FactorsAlison H. Chang, PT, DPT, MSUpon completion of this session, participants should be able to:• summarize findings of epidemiologic studies dealing with modifiablemechanical factors in knee osteoarthritis and their relationship to keyendpoints and outcomes• describe strategies that may prevent or delay disease or disabilityprogression in knee osteoarthritis, and review the quality of clinical trialevidence to support their application• explain areas for future emphasis and the work necessary to move the fieldforwardACR MEET THE PROFESSOR SESSIONS7:45 - 9:15 amFor more information, see page 60.ACR/ARHP WORKSHOPS7:45 - 9:45 amFor more information, see page 62.38

ACR/ARHP SCIENTIFIC SESSIONSACR CLINICAL SYMPOSIA9:00 - 10:30 amCEmerging Concepts in the Inflammatory MyopathiesStatin Myopathies: Emerging ConceptsLisa Christopher-Stine, MDEmerging Biomarkers in MyositisDana P. Ascherman, MDDermatomyositis Skin Disease: Novel Phenotypes in Diagnosis,Prognosis and TherapyDavid Fiorentino, MD, PhDUpon completion of this session, participants should be able to:• discuss recent advances in statin-associated myopathy• determine the appropriate workup for a patient with statin myopathy• identify emerging biomarkers in myositis and their importance• recognize the phenotypic features of dermatomyositis and their prognosticand therapeutic implicationsC cP Spondylarthropathies: Recent InsightsTumor Necrosis Factor Inhibition and Structural Progression inAnkylosing SpondylitisWalter P. Maksymowych, MDIs Methotrexate a Disease-modifying Agent in Psoriatic Arthritis?Gabrielle H. Kingsley, MBChB, PhDReactive Arthritis: Clinical Insights and Treatment OptionsJohn D. Carter, MDUpon completion of this session, participants should be able to:• outline the impact of tumor necrosis factor inhibition on the progressionof vertebral changes observed on magnetic resonance imaging inantiphospholipid syndrome patients• discuss new treatment approaches to the prevention of pathologic newbone formation in antiphospholipid syndrome• review the data on the efficacy and safety of methotrexate in prostatespecificantigen• assess if methotrexate is a disease-modifying anti-rheumatic drug inprostate-specific antigen• state the strains of chlamydia associated with reactive arthritis• summarize the recent evidence regarding the efficacy and safetyof prolonged antibiotic therapy for reactive arthritis induced bychlamydiaACR IMMUNOLOGY UPDATES FOR CLINICIANS9:00 - 10:00 amc/R Genetic Defects, Autoimmune Regulators and AutoimmunitySpeaker: Mark Anderson, MD, PhDUpon completion of this session, participants should be able to:• describe basic principles of T cell biology and selection of antigen specificresponses• evaluate how expression of self antigens in the thymus is controlled andunder the regulation of certain genetic elements• cite how impaired expression of genes such as autoimmune regulatorcan result in organ specific autoimmunity, and how this has changed ourunderstanding of autoimmune disease pathogenesisACR STATE-OF-THE-ART LECTURES9:00 - 10:00 amR Cytokine and Chemokine Regulation of Chronic PainSpeaker: Richard J. Miller, PhDUpon completion of this session, participants should be able to:• describe how the expression of inflammatory cytokines in association withtissue damage triggers diverse changes in the behavior of sensory neuronsin the context of chronic pain syndromes• summarize the actions of inflammatory cytokines synthesized by dorsalroot ganglia neurons, associated glial cells, as well as by astrocytes andmicroglia in the spinal cord• translate the knowledge of mechanisms of chronic pain generation intonovel analgesic targetsR Neutrophil Recruitment by Intravascular Danger SignalsSpeaker: Paul Kubes, PhDUpon completion of this session, participants should be able to:• define damage-associated molecular patterns and their role in theinflammatory response• list the molecular signals that direct neutrophil migration• describe the multistep cascade that allows neutrophils to sense and hometo sites of sterile inflammationACR REF SPECIAL SESSION9:00 - 10:00 amc/R ACR REF Paul Klemperer, MD Memorial Lectureship: Osteoarthritis- Quo Vadis - Where are we now - Where are we going?Speaker: Roland W. Moskowitz, MDUpon completion of this session, participants should be able to:• describe the chief epidemiologic risk factors for osteoarthritis onset• define disease pathophysiology and relationship to clinical presentations ofosteoarthritis• delineate current approaches to symptomatic and disease modification therapyACR/ARHP POSTER SESSION C AND POSTERTOURS9:00 am - 6:00 pmPoster presenters will be available from 9:00 - 11:00 AM. Poster tours will be held9:00 - 9:45 AM and 10:15 - 11:00 AM. Morning snacks will be available from 9:00- 10:30 AM.ARHP CONCURRENT ABSTRACT SESSION9:00 - 10:00 amAbstract PresentationsARHP CONCURRENT SESSIONS9:00 - 10:00 amC Adult PharmacogenomicsSpeaker: S. Louis Bridges Jr., MD, PhDUpon completion of this session, participants should be able to:• describe the major experimental approaches to identifying predictors oftreatment responses in rheumatoid arthritis• identify the obstacles to personlized medicine in rheumatoid arthritis andother complex diseases• explain what information may be learned by analysis of potentialbiomarkers and pathogenic pathways in rheumatoid arthritisTUESDAYn o v e m b e r 8 , 2 0 1 1Visit My ACR at www.rheumatology.org/annual to plan your schedule and view up to date session, abstract and syllabi information.39

ACR/ARHP SCIENTIFIC SESSIONSC Daltroy Memorial Lecture: The Role of Cultural Diversity inPatient-Health Care Provider CommunicationSpeaker: Maria E. Suarez-Almazor, MD, PhDUpon completion of this session, participants should be able to:• describe what is known about the effect of ethnic diversity on patienthealthcare provider communication• discuss current and future research on patient-health care providercommunication in rheumatologic conditions• discuss actions that health care providers can take to improve patienthealthcare provider communicationC PM PS Pregnancy and Child Care Issues for Parents withArthritisActivities for Daily Living and Instrumental Activities for Daily LivingIdeas during Pregnancy and Early Childhood Years to Help Decrease Painand FatigueAlison Hammond, PhDSplinting to Decrease Pain during Pregnancy and Early Childhood YearsCarole V. Dodge, OT, CHTUpon completion of this session, participants should be able to:• recognize common problems experienced by women with arthritis duringpregnancy, childbirth and caring for babies and young children• identify activities for daily living strategies to help parents care fornewborns and young children• review and evaluate what types of musculoskeletal conditions are commonin pregnancy and during early childhood and how splinting can helpACR PRACTICE ISSUES9:30 - 10:30 amBR cP C Understanding Medicare Incentive Programs: e-Prescribingand Physician Quality Reporting InitiativeSpeaker: Salahuddin Kazi, MDUpon completion of this session, participants should be able to:• identify the eligibility requirements for the incentive programs• review and evaluate the incentives and how they are calculated• discuss the specific dates and qualifying entities for each incentive programHow Inflammation Impacts Endothelial Function as Primary Target forCardiovascular DiseasesEric S. Stroes, MD, PhDMacrophage Death and Defective Apoptotic Cell Clearance in AdvancedAtherosclerotic Plaque ProgressionBart Staels, PhDThe Interacting Roles of Reverse Cholesterol Transport and Inflammationand Their Relationship to AtherosclerosisDaniel J. Rader, MDUpon completion of this session, participants should be able to:• review the data on the molecular pathogenesis of accelerated atherogenesisin rheumatoid arthritis and other immune-mediated inflammatorydisorders• identify the primary cellular and molecular pathways that are targeted bylocal and systemic inflammatory responses• discuss the potential targets for therapy that may reduce the cardiovascularburden as well as disease activity in rheumatoid arthritisACR CLINICAL SYMPOSIA11:00 am - noonp Periodic Fevers with Aphthous Stomatitis, Pharyngitis andAdenitisPeriodic Fevers with Aphthous Stomatitis, Pharyngitis and Adenitis:Syndrome: What It Is, What It Isn’t, and What Has Been LearnedKaryl S. Barron, MDUpon completion of this session, participants should be able to:• define the diagnostic criteria or periodic fevers with aphthous stomatitis,pharyngitis, and adenitis syndrome• recognize the differential of periodic fevers with aphthous stomatitis,pharyngitis, and adenitis syndrome• construct a diagnostic plan to evaluate children presenting with signsand symptoms compatible with periodic fevers with aphthous stomatitis,pharyngitis, and adenitis• explain research related to immunologic phenomena identified in patientswith periodic fevers with aphthous stomatitis, pharyngitis, and adenitissyndromeTUESDAYn o v e m b e r 8 , 2 0 1 1EXHIBITS AND REPLAY CAFÉ10:00 am - 5:00 pmACR WORKSHOPS10:30 am - 12:30 pmFor more information, see page 62.INNOVATION THEATER10:30 - 11:15 amInnovation Theater presentations will be listed in My ACR atwww.rheumatology.org/annual in early September.ACR BASIC SCIENCE SYMPOSIUM11:00 am - 12:30 pmr Towards Prevention of Atherosclerosis Progression in RheumatoidArthritis: Insights into the Relationship between Inflammation andCardiovascular Disease11:00 am - 12:30 pmC cP The Three Ps of Dermatologic and Autoimmune Disease:Pyoderma, Panniculitis and Pemphigus/PemphigoidPyoderma Gangrenosum: An Overlap of Dermatologic and RheumaticDiseaseJeffrey P. Callen, MDPanniculitis: What Should a Rheumatologist Know?Lela A. Lee, MDPemphigus and the Pemphigoid DiseasesVictoria P. Werth, MDUpon completion of this session, participants should be able to:• describe the pathophysiology and immunology associated with pyoderma,panniculitis and pemphigus/pemphigoid• recognize and formulate a differential diagnosis for these three conditions• identify new treatment strategies including the use of disease-modifyinganti-rheumatic drugs and biological medications as possible treatmentoptionsc/R ACR PLENARY SESSION III: DISCOVERY 20114011:00 am - 12:30 pmACR Abstract Presentation and Commentaries

ACR/ARHP SCIENTIFIC SESSIONSACR PRACTICE ISSUES11:00 am - 12:30 pmBR cP CORC Forum: Payment Reform OptionsUnderstanding the Payment Options for TomorrowWarren Skea, PhDMichael S. Barr, MD, MBAUpon completion of this session, participants should be able to:• identify the various payment approaches including the use of managedcare organizations and accountable care organizations• explain the challenges and opportunities facing the Accountable CareOrganizations and Patient-Centered Medical Homes models today• identify how these new payment options will be used in promoting quality,efficiency and improved outcomesARHP CONCURRENT SESSIONS11:00 - noonr Are You Losing It? How to Deal with Loss to Follow Up inResearch Studies and Clinical TrialsHow Does Loss to Follow Up Happen and What Are the Implications?Robert R. McLean, DSc, MPHHow to Avoid or Deal with Loss to Follow UpJean P. Dufour, MDUpon completion of this session, participants should be able to:• outline the consequences of loss to follow up• describe how loss to follow up affects interpretation of research studies• recognize the analytic techniques used to handle loss to follow up• employ practical methods to reduce loss to follow upc/R PMArthritis and Traditional Chinese MedicineSpeaker: Chenchen Wang, MD, MScUpon completion of this session, participants should be able to:• explain traditional Chinese medicine treatments for arthritis• describe how evidence can be integrated into alternative treatments forarthritis• apply strategies for treatment interventions that focus on mind-bodytherapies for chronic pain• discuss how alternative treatments can be utilized in clinical practiceC Entrapment Neuropathies and Nerve Conduction StudiesSpeaker: Hans L. Carlson, MDUpon completion of this session, participants should be able to:• review the timing of ordering nerve conduction studies• assess whether the studies’ conclusions are consistent with the clinicalassessment• discuss management options based on outcomesBR Fiscal Management of Infusion Clinics: Academic and PrivatePractice PerspectivesHow to Successfully Manage an Infusion Center in the Academic SettingVictoria L. Ruffing, RNHow to Successfully Manage an Infusion Center in the Private PracticeSettingKaren M. Ferguson, MD, PhDUpon completion of this session, participants should be able to:• recognize how infusion clinics may affect patients and practices• describe the steps necessary to manage a successful infusion clinic• identify patient assistance and government programs available to help withpatient infusion therapy costs• discuss how future processes may need occupational therapy change inorder to remain successful in the ever changing health care marketplaceARHP SPECIAL SESSIONnoon - 1:00 pmNetworking BreakAll attendees are cordially invited. Grab your lunch and join a group.INNOVATION THEATER12:30 - 1:15 pmInnovation Theater presentations will be listed in My ACR atwww.rheumatology.org/annual in early September.ACR MEET THE PROFESSOR SESSIONS12:45 - 2:15 pmFor more information, see page 60.ACR CLINICAL SYMPOSIUM1:00 - 2:00 pmC cP Hyperuricemia and Gout: Mechanisms and Morbidity (ClinicalReview)Speaker: Michael H. Pillinger, MDUpon completion of this session, participants should be able to:• explain the mechanisms by which hyperuricemia leads to gouty arthritis• discuss the possible long-term consequences of sustained hyperuricemia• outline treatment options for patients with hyperuricemia and gout withemphasis on newer therapiesACR PRACTICE ISSUES1:00 - 2:00 pmBR C cP Mastering Patient Flow to Improve Practice OperationsSpeaker: Owen J. Dahl, MBA, FACHE, CHBC, LSSMBBUpon completion of this session, participants should be able to:• identify best practices on improving patient flow and efficiency in theexam room• outline proven tools, self-assessments, worksheets to center effectiveworkflow for each patient visit• describe new technology trends in the process of improving practiceoperations and patient flowACR SPECIAL SESSIONS1:00 - 2:00 pmACR Leadership Town Hall Meeting and Business MeetingThis session is not eligible for CME credit.Speakers: David G. Borenstein, MDJames R. O’Dell, MDJoseph Flood, MDAudrey B. Uknis, MDE. William St.Clair, MDNadine T. James, RN, PhDTUESDAYn o v e m b e r 8 , 2 0 1 1Visit My ACR at www.rheumatology.org/annual to plan your schedule and view up to date session, abstract and syllabi information.41

ACR/ARHP SCIENTIFIC SESSIONSTUESDAYn o v e m b e r 8 , 2 0 1 1BR Ed. F Education Redesign for Teaching RheumatologistsEducational Redesign in RheumatologyLyle Berkowitz, MDUpon completion of this session, participants should be able to:• develop milestones for rheumatology training, from medical schoolthrough fellowship• discuss how to increase training efficiency• innovate processes to help guarantee the preparation of appropriatelytrained rheumatologistsACR STUDY GROUPS1:00 - 2:00 pmView complete session details in My ACR at www.rheumatology.org/annual.Study Groups are not eligible for CME credit.Clinician Educator Study GroupEconomic Evaluations: Measurement of Work and WorkerProductivityGeographic Variation in Rheumatology WorkforceHuman Regulatory T Cell BiologyHypermobility IIInterdisciplinary Arthritis Management GroupJuvenile UveitisMacrophage Activation SyndromeMyositis Study Group: New Developments in Myositis TherapiesNeuro Endocrine Immunology Study GroupOsteoarthritisPatient Feedback, Treatment Adherence and Disease OutcomesPsoriatic Arthritis Working GroupSkin DiseasesACR WORKSHOPS1:15 - 3:15 pmFor more information, see page 62.ACR BASIC SCIENCE SYMPOSIA2:30 - 4:00 pmr Mechanisms of Lymphoma Development in Systemic AutoimmuneDiseaseAutoimmunity and LymphomagenesisLynn R. Goldin, PhDMechanisms of Non-Hodgkin’s Lymphoma in Sjögren’s SyndromeXavier Mariette, MDPathogenic Mechanisms of Lymphoma Development in AutoimmuneDiseaseArne Hansen, MDUpon completion of this session, participants should be able to:• summarize the specific autoimmune diseases that have been demonstratedto be associated with an increased risk of lymphoma development, includingthe specific autoimmune diseases and lymphoma types, the strength of thoseassociations, and limitations of the studies performed to date• discuss the disease features that characterize Sjögren’s syndrome patientsof greatest risk of lymphoma development and the etiologic mechanismsimplicated by those associations• describe the genes and pathways that are implicated in the development ofboth autoimmune disease and lymphoma based on their roles in inhibitinguncontrolled B cell growthR Next-Generation Sequencing Applied to Rheumatic DiseasesLarge-Scale Sequencing in Patients with Rheumatoid ArthritisPeter K. Gregersen, MDRole of T cell Receptor Sequencing in Rheumatic DiseasesNiek De Vries, MD, PhDSequencing of Immunoglobulin Repertoires in Rheumatoid ArthritisWilliam Robinson, MD, PhDUpon completion of this session, participants should be able to:• define the role of next-generation sequencing in scientific discovery• recognize the difference between common and rare variants• describe the role of T cell receptor and immunoglobulin locus inrheumatoid arthritis pathogenesisACR CLINICAL SYMPOSIA2:30 - 4:00 pmC PMThe Neuromuscular System in OsteoarthritisSomatosensory Dysfunction and OsteoarthritisNajia Shakoor, MDMuscle Weakness and OsteoarthritisEwa M. Roos, PT, PhDNeuromuscular Training in OsteoarthritisLaura E. Thorp, MPT, PhDUpon completion of this session, participants should be able to:• describe afferent somatosensorty deficits commonly observed in lowerextremity osteoarthritis• explain the role of muscle weakness in osteoarthritis onset and progression• review current thoughts on the role of muscle training in osteoarthritistherapyC cP Vasculitis: Key Issues for the Clinician in Three UniqueDiseasesChurg-Strauss SyndromeMichael E. Wechsler, MMSc, MDPrimary Angiitis of the Central Nervous SystemRula Hajj-Ali, MDTakayasu’s ArteritisPeter A. Merkel, MD, MPHUpon completion of this session, participants should be able to:• describe the similarities and differences for the management of asthmaand vasculitis in Churg-Strauss syndrome• recognize how to differentiate primary angiitis of the central nervoussystem from other central nervous system diseases• identify the role of different imaging techniques in Takayasu’s arteritis andhow useful they are in assessing disease activityACR CONCURRENT ABSTRACT SESSIONS2:30 - 4:00 pmACR Late-breaking Abstracts and Abstract Presentations42

ACR/ARHP SCIENTIFIC SESSIONSARHP CONCURRENT SESSIONS2:30 - 4:00 pmc/R PMBeyond Pain and Fatigue: Expanding Clinician and ResearcherFocus to Improve Daily LifeConceptualizing Participation: Measuring More than SymptomsMonique A. Gignac, PhDCurrent Status of Participation MeasuresRoss Wilkie, PhDParticipation Outcomes in Everyday PracticeCatherine L. Backman, PhD, OT(C)Summary of Participation Outcomes with Audience DiscussionPatricia P. Katz, PhDPanel DiscussionUpon completion of this session, participants should be able to:• apply a bio-psychosocial approach to the assessment and managementof social participation and social roles in adults with musculoskeletalconditions• describe individual and general factors that are important whendetermining restricted social participation in older adults with joint pain• compare and contrast the multi-national approaches to the assessment andrehabilitation of restriction in social participationC Extrarticular Manifestations of Rheumatoid Arthritis:Ophthalmologic, Pulmonary and CardiovascularEye Disease ManifestationsJames T. Rosenbaum, MDCardiovascular ManifestationsJoan M. Bathon, MDPulmonary Manifestations of Rheumatoid ArthritisSpeaker to be announcedUpon completion of this session, participants should be able to:• enumerate the ophthalmic manifestations of rheumatoid arthritis• discuss the etiology of increased cardiac risk in rheumatoid arthritispatients• develop a plan for management of interstitial lung disease in a patient withrheumatoid arthritisC Keep People with Arthritis Working: An Interactive Case-basedDiscussionCase PresentationsNancy A. Baker, ScD, MPH, OTR/LJulie J. Keysor, PhD, PTDiane V. Lacaille, MD, MHScSaralynn H. Allaire, ScDUpon completion of this session, participants should be able to:• identify solutions that could help work-related challenges• discuss solutions for arthritis work-related challenges• review a range of issues that patients may encounter, including ergonomicchanges, physical job accommodations, energy balance and advocacyC Practice PotpourriMy Patient’s Irate - What Do I Do?Dennis J. Boyle, MDStretching vs. Strengthening in Fibromyalgia - What Should I Prescribe?Kim D. Jones, PhDCan I Diagnose Gout without Crystal Analysis?Pascale Schwab, MDI Have a Patient in Pain with a Monoclonal Gammopathy - Is ThisMonoclonal Gammopathy of Undetermined Significance?Timothy E. Caragher, PhDHip Osteoarthritis with Limb Length Discrepancy of 1 inch - Is ItSignificant?Jill Ferrari, PhD, BSc(Hons)Upon completion of this session, participants should be able to:• review strategies to deal effectively with a difficult patient• discuss exercise prescriptions for fibromyalgia• review crystal analysis in the diagnosis of gout• interpret an abnormal serum protein electrophoresis• review osteoarthritis and limb length discrepancyINNOVATION THEATER2:30 - 3:15 pmInnovation Theater presentations will be listed in My ACR atwww.rheumatology.org/annual in early September.ACR WORKSHOPS4:00 - 6:00 pmFor more information, see page 62.ACR BASIC SCIENCE SYMPOSIA4:30 - 6:00 pmr New Concepts in the Autoimmune Pathogenesis of InterstitialLung DiseasesOverview of Pathogenic Concepts in the Interstitial Lung DiseasesCarol A. Feghali-Bostwick, PhDT Cell Dependent Regulation of FibrogenesisMatthias Mack, MDFibrocytes in Autoimmune FibrosesErica Herzog, MD, PhDUpon completion of this session, participants should be able to:• identify current concepts of the immune pathogenesis of interstitial lungdiseases• describe the role of fibrocytes in systemic fibroses and their biomarkerpotential• analyze the adaptive immune mechanisms that may govern fibrogenesisr Osteoarthritis: A Disease of the Joint as an OrganHow Understanding Joint Development Can Contribute to a NewUnderstanding of OsteoarthritisMaurizio Pacifici, PhDThe Role of Synovial Inflammation in OsteoarthritisWim B. Van Den Berg, PhDThe Subchondral Bone and Osteoarthritis: Not Just Hard TissueHarrie Weinans, PhDTUESDAYn o v e m b e r 8 , 2 0 1 1Upon completion of this session, participants should be able to:• recognize osteoarthritis as a condition of the entire joint as an organ• identify developmental processes within the joint that may contribute tothe development of osteoarthritisVisit My ACR at www.rheumatology.org/annual to plan your schedule and view up to date session, abstract and syllabi information.43

ACR/ARHP SCIENTIFIC SESSIONSTUESDAYn o v e m b e r 8 , 2 0 1 1• define the synovial changes that occur in osteoarthritis and discuss howsynovitis may contribute to disease progression• relate the changes in the subchondral bone to joint tissue changes inosteoarthritisACR CLINICAL SYMPOSIA4:30 - 6:00 pmC cP Challenging Complications of Systemic SclerosisCardiac Involvement from SclerodermaYannick Allanore, MD, PhDGastrointestinal Involvement in SclerodermaRomy Christmann, MD, PhDScleroderma Associated Arthritis, Tendon Rubs, Neuropathy andVasculitisVirginia D. Steen, MDUpon completion of this session, participants should be able to:• recognize the cardiac complications of scleroderma and the currentevidence to guide management of these complications• recognize the gastrointestinal complications associated with sclerodermaand apply the current evidence to managing patients with thesecomplications• discuss some of the challenging complications of scleroderma includingarthritis, tendon rubs, neuropathy and vasculitisc/R PSDeveloping ACR Guidelines for the Treatment of GoutSpeakers: Puja P. Khanna, MD, MPHDinesh Khanna, MD, MScRobert Terkeltaub, MDUpon completion of this session, participants should be able to:• explain the process used to develop gout treatment guidelines• describe treatment guidelines for management of acute gouty arthritis• describe treatment for serum urate lowering therapy• discuss treatment guidelines for management of chronic tophaceous goutC Extra Glandular Manifestations of Sjögren’s SyndromeThe Nervous System and Sjögren’s SyndromeJulius Birnbaum, MDEvidence to Support B Cell Therapy in Sjögren’s SyndromeXavier Mariette, MDUpon completion of this session, participants should be able to:• describe the diverse presentations of involvement of the central nervoussystem in Sjögren’s syndrome• describe the diagnostic approach to and manifestations of small fiberneuropathy in Sjögren’s syndrome• discuss the evidence to support the use of B cell therapies in Sjögren’ssyndromeP/C PMThe Child with Chronic PainThe Neurobiology of PainMichael Henrickson, MD, MPHThe Role of Coping Skills Strategies and Behavioral Intervention in theTreatment of Juvenile FibromyalgiaSusmita Kashikar-Zuck, PhDAerobic Exercise and its Role in the Treatment of Juvenile Fibromyalgiaand Juvenile Idiopathic ArthritisBrian M. Feldman, MD, MScUpon completion of this session, participants should be able to:• discuss the intricacies of how the central nervous systems networks,the autonomic nervous system , the endocrine system and the immuneresponse system interweave in the recognition of pain• construct a treatment plan for patients with juvenile fibromyalgiaincorporating modalities that include measures aimed at the neurobiologyof pain to include non-pharmacologic therapies including effectivebehavioral interventions and aerobic exerciseACR MEET THE PROFESSOR SESSIONS4:30 - 6:00 pmFor more information, see page 60.ACR SPECIAL SESSIONS4:30 - 6:00 pmc/R cP ACR Knowledge BowlUpon completion of this session, participants should be able to:• recall factual information related to the rheumatic diseases• integrate basic principles of rheumatology into clinical practice• identify key images that are important to recognize in rheumatologyclinical practicecP C Insurance RoundtableThis session is not eligible for CME credit.Speakers: Rodolfo Molina, MDAlex Limanni, MDUpon completion of this session, participants should be able to:• discuss key areas of the claims processing systems to improve efficiency andreduce denials• identify ways to minimize the prior authorizations administrative burdenfor physician practices• discuss strategies and guidelines for the use of biologic drug therapy toimprove managementACR AND ARHP CONCURRENT ABSTRACTSESSIONS4:30 - 6:00 pmAbstract PresentationsARHP CONCURRENT SESSIONS4:30 - 6:00 pmC PSDesigning Exercise Prescriptions for Individuals with Arthritisand Other Comorbidities: What are the Considerations?Risk Factor Stratification/Guidelines for Exercise Testing and Prescription:General Considerations for Individuals with Arthritis and CardiovascularDiseaseMary E. Christenson, PT, PhDExercise Prescription for Individuals with Rheumatoid Arthritis andComorbiditiesMaura D. Iversen, PT, DPT, SD, MPHCase Studies Considering Comorbid Conditions: Osteoarthritis andObesity, and Osteoarthritis and Pre-diabetesMary E. Christenson, PT, PhD and Maura D. Iversen, PT, DPT, SD, MPHUpon completion of this session, participants should be able to:• identify consequences of physical activity for persons with arthritis incombination with other comorbidities• examine the current evidence related to prescribing exercise in individualswith arthritis and other comorbidities44

ACR/ARHP SCIENTIFIC SESSIONSRheumatology Private Practice CareerRobin K. Dore, MDRheumatologists in the Pharmaceutical IndustryWayne H. Tsuji, MDRheumatologists in GovernmentFrederick W. Miller, MD, PhDUpon completion of this session, participants should be able to:• identify different career choices available to young rheumatologists• describe the workload, work-life balance and rewards of various careerpaths• appraise the pros and cons of the various career choices in rheumatologyACR CONCURRENT ABSTRACT SESSIONS9:00 - 10:30 amAbstract Presentations• discuss the pathophysiology of synovitis, acne, pustulosis, hypersostosis andosteitis syndrome• review the treatment options for chronic recurrent multi-focal osteomyelitisc/R Introduction to Comparative Effectiveness Research Study Designsfor Rheumatology Health ProfessionalsIntroduction to Comparative Effectiveness Research Methods and Top 100PrioritiesJennifer M. Hootman, PhDRandomized Controlled Trials: Mind-body Interventions for RheumatoidArthritisSusan J. Bartlett, PhDObservational Studies: Using Rheumatic Disease Registry Data forComparative Effectiveness ResearchKaleb D. Michaud, PhDSystematic Reviews/Meta-analyses: Exercise for Adults with ArthritisJennifer M. Hootman, PhDARHP CONCURRENT ABSTRACT SESSION9:00 - 10:00 amAbstract PresentationsARHP CONCURRENT SESSIONS9:00 - 10:00 amR Analysis of Large Databases: Rheumatology ResearchOpportunitiesOverview of the National Institutes of Health-funded Center forRehabilitation Research Using Large DatasetsJames E. Graham, PhD, DCStrengths and Limitations of Selected Large DatasetsAnne Deutsch, RN, PhD, CRRN and James E. Graham, PhD, DCExamples of Current Use of Large Datasets to Address Health Policy IssuesAnne Deutsch, RN, PhD, CRRNUpon completion of this session, participants should be able to:• state research involving large national datasets, including specificopportunities through an NIH-funded consortium dedicated to increasingrehabilitation-related research capacity• identify and describe available datasets that may be relevant forrheumatology-related investigations, and the strengths and limitations ofthese datasets• describe current research and policy activities involving the use of largedatasets, and future directions of this workC Chronic Non-bacterial OsteomyelitisChronic Recurrent Multifocal OsteomyelitisSara M. Stern, MDSynovitis, Acne, Pustulosis, Hypersostosis and OsteitisRobert D. Inman, MDAutoimmune Diseases Associated with Synovitis, Acne, Pustulosis,Hypersostosis and Osteitis Syndrome, and Chronic Recurrent MultifocalOsteomyelitisPolly J. Ferguson, MDUpon completion of this session, participants should be able to:• define and develop a differential diagnosis for chronic non-bacterialosteomyelitisUpon completion of this session, participants should be able to:• define comparative effectiveness research• review the Institute of Medicine’s top 100 research priorities forcomparative effectiveness research relevant to non-pharmaceuticaltreatments in rheumatology• list the most used study designs in comparative effectiveness research• apply examples of commonly used CER study designs in rheumatologyresearchACR BASIC SCIENCE SYMPOSIUM11:00 am - 12:30 pmR PMPain Pathways in Rheumatic DiseasesAnimal Models for Pain Associated with ArthritisJason J. McDougall, PhDGenetic Variation in Human Pain PerceptionWilliam Maixner, DDS, PhDTumor Necrosis Factor - alpha Blockade Rapidly Inhibits Pain Responsesin the Central Nervous SystemGeorg Schett, MDUpon completion of this session, participants should be able to:• review the rationale and evidence for various animal models for studyingpain in the context of rheumatic diseases, both inflammatory and noninflammatory• acknowledge how both rare genetic variants and common geneticpolymorphisms are mediators of pain perception and clinical painphenotypes, in the context of musculoskeletal pain• discuss how TNF-á neutralization affects nociceptive brain activity in thecontext of arthritis, long before it achieves antiinflammatory effects inthe jointsACR CLINICAL SYMPOSIA11:00 am - 12:30 pmc/R Biosimilar Products in the U.S. Market: Fact or Fiction?Introduction to BiosimilarsGeoffrey Eich, MSThe European Medicines Agency Guidelines for BiosimilarsAndrea Laslop, Professor, MDDeveloping a Regulatory Path in the U.S.Vibeke Strand, MDWEDNESDAYn o v e m b e r 9 , 2 0 1 1Visit My ACR at www.rheumatology.org/annual to plan your schedule and view up to date session, abstract and syllabi information.47

ACR/ARHP SCIENTIFIC SESSIONSUpon completion of this session, participants should be able to:• describe the difference between biosimilar and generic drug products• identify the complexity of large protein production and implications forbiologic activity• describe the general requirements for licensing a biosimilar product inEurope• cite the proposed requirements for licensing a biosimilar in the U.S.P/C PSUpdate on Safety Issues in the Treatment of RheumaticDiseases – From the FDA and BeyondIntroduction – Update on Newly Identified Drug Safety IssuesArthur Kavanaugh, MDUpdate and Safety Issues of Recently Approved Agents for RheumaticDiseasesSarah K. Okada-Yim, MDThe Year in Review – Update on Safety Issues at the Food and DrugAdministrationSally M. Seymour, MDPanel DiscussionUpon completion of this session, participants should be able to:• identify important safety issues in the drug treatment of rheumatic diseases• integrate knowledge of new safety issues into their treatment strategies• explain patients about the safety issues related to treatments for rheumaticdiseases• explain evolutions at the Food and Drug Administration that will affectdrug safety monitoring and reportingACR STATE-OF-THE-ART LECTURE11:00 am - noonr The Role of Extracellular Ribonucleic Acid in InflammatoryProcessesSpeaker: Klaus T. Preissner, PhDUpon completion of this session, participants should be able to:• identify the potential role of extracellular ribonucleic acid in inflammationand immunity• describe the function of endogenous, vascular RNase1 as vessel protectiveand antithrombotic factor• evaluate the possibility of other extracellular RNA-binding proteins tobecome influenced in their activity by ribonucleic acidsACR AND ARHP CONCURRENT ABSTRACTSESSIONS11:00 am - 12:30 pmAbstract PresentationsARHP CONCURRENT SESSIONS11:00 am - 12:30 pmC Lower Extremity Musculoskeletal Assessment of the RheumatologyPatientSpeaker: Christopher Bise, DPTUpon completion of this session, participants should be able to:• describe key components of a lower quarter examination for therheumatology patient• identify common objective findings of the rheumatology patient• discuss interventions available for the rheumatology patient based on theresults of the musculoskeletal evaluationC Policy and Environmental Strategies to Support Increased PhysicalActivity for Adults with Arthritis: Findings from a Centers for DiseaseControl/Arthritis Foundation Expert PanelThe Process: Defining Appropriate Audiences, Settings and KeyInformantsJennifer M. Hootman, PhDThe Product: Prioritized List of Environmental Strategies and Policies toSupport Increased Physical Activity among Adults with ArthritisTeresa J. Brady, PhDUpon completion of this session, participants should be able to:• identify settings and audiences that influence environmental strategies andpolicies for promoting physical activity among adults with arthritis• categorize environmental strategies and policies that should reduce barriersand strengthen facilitators to physical activity for persons with arthritis• list prioritized environmental strategies and policies developed by a panelof expertsINDUSTRY-SUPPORTED POST CONFERENCESYMPOSIA1:00 - 4:00 pmFor CME-accredited symposia, the sponsoring organization is responsible for planningand providing CME credit.WEDNESDAYn o v e m b e r 9 , 2 0 1 148

Maximize Your AnnualMeeting Experience withSessionSelect!registration & preliminary programOver$500 ofaddedvalue!Register for the annual meeting and receive FREE onlineaccess to hundreds of hours of annual meeting content—over $500 of added value!Within 24 hours of virtually every live session*, videorecordings of the presentations, including oral abstractsessions, will be available through SessionSelect, yoursource for ACR education, online. No need to missa session!Recorded sessions* will be available to view aswebcasts during and after the meeting.* Ticketed sessions not included. CME credit is not available for online viewing.The ACR thanks Genentech, A Member of the Roche Group, for theirsupport of the 2011 ACR/ARHP Annual Scientific Meeting SessionSelect.Visit www.rheumatology.org/annual toregister for the 2011 annual meeting today!

GENERAL INFORMATIONImportant Dates• Member housing and registration opens: 9:00 am ET, Wednesday,June 8• Non-member housing and registration opens: 9:00 am ET,Wednesday, June 22• Last day to register at “Early-Bird” rate: Friday, September 9On-site Registration Hours:Friday, November 4Saturday, November 5Sunday, November 6Monday, November 7Tuesday, November 8Wednesday, November 96:30 am – 6:00 pm6:30 am – 6:30 pm6:30 am – 6:00 pm6:30 am – 6:00 pm6:30 am – 6:00 pm7:00 am – 1:00 pm• Last day to register at reduced “Advance” rate: Friday, October 21LocationMcCormick Place West2301 South Lake Shore DriveChicago, IL 60616www.mccormickplace.comThe co-headquarter hotels are Hilton Chicago and the Palmer HouseHilton.Daylight SavingsBe sure to set your clock back one hour before you go to bed onSaturday, November 5 as Daylight Savings Time ends at 2:00 am,Sunday, November 6. This means you get an extra hour of sleep!Affiliate EventsWould you like to host an affiliate event such as an advisory board,alumni reception, committee meeting, focus group, investigatormeeting or non-profit social event? If so, please review your optionsand submit your application online. Everything you need to knowcan be found at www.rheumatology.org/annual. Remember, allevents must be approved by the ACR.Announcement BoardsDisplay boards will be available in the convention center for postingevents of interest. Posted materials are limited to 8.5” x 11” in size.Location will be published in the final program book.502011 Fellows-in-Training Annual Meeting ScholarshipThe ACR is pleased to announce the Fellows-in-Training Annual Meeting Scholarship, designedto expose fellows-in-training to the ACR 2011ARHP/ACR Annual Scientific Meeting. TheFellows-In-Training Scholarship provides firstand second year fellows-in-training memberswith complimentary registration to one premeetingconference and scientific sessions atthe annual meeting. Support will be providedfor five nights’ shared accommodation, airfareand an invitation to attend a special educationsession.Fellows interested in this opportunity must bea first or second-year adult or first, second orthird-year pediatric fellow in a rheumatologytraining program approved by the AccreditationCouncil of Graduate Medical Education or theRoyal College of Physicians and Surgeons ofCanada. Preference is given to applicants whoare ACR Fellow-in-Training members or whohave submitted a completed application forFellows-in-Training membership beforeJuly 11, 2011.Scholarship registration opens Friday, July15 and closes Monday, August 8. For moreinformation, please visit www.rheumatology.org/education/annual/student_trainee_awards.asp or e-mail fittravel@rheumatology.org.The ACR wishes to thank Centocor OrthoBiotech, Inc., and Genentech, A Member of theRoche Group, for their support of the 2011 ACRAnnual Scientific Meeting Fellows-In-TrainingTravel Scholarship.The ACR wishes to thank the following organizations for their generoussupport of the 2011 Fellows Education Fund:AbbottBristol-Myers Squibb Company

egistration & preliminary programCall for Clinical Trials/Registry InformationThe Clinical Trials/Registry Information Poster Exhibit is designedto promote awareness of clinical trials, registries, repositories andcohorts related to rheumatology and rheumatic diseases. The exhibitwill provide interested parties with the opportunity to display anunmanned informational poster. The poster should be designedto inform attendees about the activities and provide contactinformation for attendees to obtain follow-up information.If you are interested in displaying a clinical trial/registry informationposter visit www.rheumatology.org/annual and submit yourapplication by the deadline of August 1, 2011.Career ConnectionsEmployers and job seekers are invited to visit the ACR CareerConnections kiosk in the exhibit hall to search the job listings oradvertise an opening. For promotional rates available to employers,visit www.rheumatology.org/education/careers. See page 57 formore information.EmployersIf you’re looking to bring in a new associate, hire a rheumatologistfor an academic/research position or sell your practice, ACR CareerConnections can help you gain exposure and visibility to reach yourtarget audience.Job SeekersWhether you’re looking for a clinical or academic/researchposition, interested in purchasing an established practice or startingyour own, ACR Career Connections will help you make the rightconnections.ChildrenChild CareThe ACR has contracted with KiddieCorp to provide child care duringthe meeting. KiddieCorp will offer one program for children 6 months– 3 years and a second program for children 4–12 years old. The feeis $9* per hour, per child (2 hour minimum). This service is available toregistered attendees only.*As a benefit for ACR members who are trainees, medical students,residents; as well as ARHP student members, this service will beprovided a complimentary benefit.Child care services will be available:KiddieCorp team members are uniformed,qualified, screened, bonded, and experiencedemployees who have completed the KiddieCorptraining program. This intensive screening andtraining process ensures that KiddieCorp clientsreceive the highest –quality care and consistency. For moreinformation on KiddieCorp visit their Website at www.kiddiecorp.com, e-mail info@kiddecorp.com or call (800) 942-9947.To enroll or to learn more about KiddieCorp’s services, log on towww.kiddiecorp.com/acrkids.htm. Space is limited, so reserve yourspot today!Nursing Mother’s RoomDuring scientific session hours, a staffed Nursing Mother’s room willbe available in the convention center. This room will have privateseating areas, a refrigerator and a bulletin board for informationexchange, advice and suggestions.For safety reasons, strollers are not permitted in the exhibit halland all children must be accompanied by an adult. Only registeredattendees will be permitted into meeting rooms.MediaCredentialed media attend the annual meeting to cover stories forconsumer, trade and other media outlets, and are easily identifiedby their black press ribbons. Media has access to all general sessionsand limited access (at the discretion of speakers) to Meet theProfessor and Workshop sessions.Media may use hand-held audio recorders and still cameras;moving video recording is also permitted with the permission ofthe presenter(s). The exception to this policy is that an exhibitmay not be photographed or videotaped without the permissionof the authorized exhibitor. Attendees who have questionsabout the ACR’s media policies should contact Suzanne Forteat sforte@rheumatology.org.Meeting Room CapacityAttendance at scientific sessions is on a first-come, first-served basis.Rooms which have reached the maximum capacity may be closedaccording to local fire and safety regulations. Sessions closed dueto overcrowding may be available on SessionSelect.51Friday, November 4:Saturday, November 5:Sunday, November 6:Monday, November 7:Tuesday, November 8:Wednesday, November 9:7:00 am – 6:00 pm7:00 am – 6:30 pm7:00 am – 6:30 pm7:00 am – 6:30 pm7:00 am – 6:30 pm7:00 am – 1:00 pmVisit My ACR at www.rheumatology.org/annual to plan your schedule and view up to date session,abstract and syllabi information.

52Opening Event at the Field Museum ofNatural HistorySaturday, November 57:00 – 10:00 pmExplore the Field Museum with its encyclopediccollection of cultural objects and biologicalspecimens from around the world. And don’tforget to say hello to Sue – the largest and mostcomplete Tyrannosaurus rex fossil ever unearthed. Be sure to comehungry as we will be featuring “A Taste of Chicago” menu.Tickets are $40. Space is limited so order your tickets early. See page3 for more information.Photographs and Video RecordingAs a courtesy to our presenters, ACR policy does not permitphotographs or recordings during the educational sessions includingposter sessions. For questions about the ACR’s media policies,contact Suzanne Forte at sforte@rheumatology.org.REF Donors’ LoungeACR Research and Education Foundation donors should plan tospend time in the Donors’ Lounge and take advantage of specialperks! Enjoy a hot breakfast each morning and gourmet afternooncoffee breaks; catch up on work and check e-mail at one of theprivate computer stations; or relax by watching some television andcatching up with your colleagues.An official 2011 Donors’ Lounge Access Pass is required for entry andwill be distributed to qualified donors at the meeting. A minimumcumulative donation of $500 to the REF Annual Giving Campaignduring fiscal year 2011 (July 1, 2010 through June 30, 2011) qualifies.Special NeedsTo ensure we can accommodate your needs please indicate yourrequirements on your registration form. If you have any questionsplease contact Ron Olejko at olejko@rheumatology.org or (404) 633-3777 x312.Wheelchair and Scooter RentalsMcCormick Place also offers on-site rentals of mobility scooters,wheelchairs, PowerChairs and oxygen equipment through itspreferred mobility service partner, Scootaround, Inc. Mobilityequipment can be reserved in advance and will be waitingat McCormick Place or can be delivered to your hotel. Dailyand weekly rates are available withoperators on call 24/7 at (888)441-7575 or by visiting www.scootaround.com/rentals/m/mccormickplace.Wi-Fi Access and Recharge AreasTo make it easier to access online meeting materials,complimentary Wi-Fi access will be available in all roomsof McCormick Place West. Re-charge areas will be availablein the exhibit hall and throughout McCormick Place West.TRAVEL GUIDEMember Housing and Registration Opens:9:00 am ET, Wednesday, June 8Non-Member Housing and Registration Opens:9:00 am ET, Wednesday, June 22Getting Downtown from AirportThe major gateway to Chicago is O’Hare International Airport (ORD),located 18 miles northwest of downtown. Midway InternationalAirport (MDW) is located about 12 miles southwest of downtownand attracts more discounted airlines.A cab ride into the city will cost about $45 from ORD and about$30 from MDW. During rush-hour, due to wait time in traffic, thefare will be higher. Public transportation is available from bothairports for $2.25 on the El (elevated train) to downtown Chicago.ORD is on the Blue Line and MDW is on the Orange Line. Airportshuttles are available at both airports for approximately $23 -$28. Reservations are not necessary from the airport but arerecommended for return trips.Shuttle Bus/ADA Transportation ServicesMcCormick Place West is approximately two miles south ofdowntown Chicago. ACR will provide a complimentary shuttlebus service to/from ACR contracted hotels and McCormick PlaceWest during morning and afternoon peak hours. During non-peakhours, ACR will provide complimentary shuttle bus service to/fromMcCormick Place West and selected central downtown locationsfrom which you can walk to your specific hotel and other venues indowntown Chicago.Complimentary shuttle bus services will be provided only forthose staying in ACR contracted hotels. Attendees staying in noncontractedACR hotels may purchase an ACR shuttle bus pass inadvance or on site at the ACR registration counter for $40.Wheel chair accessible vans can be scheduled upon request betweenofficial ACR hotels and McCormick Place West. Visit the ACR ShuttleBus Desk at the McCormick Place West. Arrangements can also bemade in advance by Chicago Travel Consultants at (773) 619-2274or jszostak@ctcdmc.com.ACR will provide a complimentary shuttle bus service to/from ACR contracted hotels and McCormick Place Westduring morning and afternoon peak hours.

egistration & preliminary programACR EXHIBIT HALLExhibit Hall HoursSunday, November 6: 10:00 am – 5:00 pmMonday, November 7: 10:00 am – 7:00 pmTuesday, November 8: 10:00 am – 5:00 pmNetwork with exhibitors and colleagues• Enjoy daily refreshment breaks at 10:00 am and 2:30 pm• Unwind at the Wine and Cheese Reception on Monday, November 7: 5:00 - 7:00 pm• Connect with a colleague in one of the Networking Lounges or in the food courtLearn about the latest rheumatologyproducts and services• Compare products and services at over 150 exhibiting companies – over 25 new exhibitors will bepresent this year• Discover state-of-the-art innovations and check out what new patient education resources are available• Hear about the latest product innovations and news in the Innovation TheaterExplore what the Exhibit Hall has to offer• View a missed session at the Replay Café, presented by SessionSelect• Meet potential employers and employees at ACR Career Connection• Recharge yourself and your electronics at one of the Recharge Lounges• Ship your meeting materials home for free – visit the exhibit hall on Tuesday, November 8 to learn how53Getting Around ChicagoTaxi fare from downtown Chicago to McCormick Place West isapproximately $10-15.For $2.25, you can take the No. 3 bus whichtravels on Michigan Avenue to the front door of McCormick PlaceWest. Or, for $2.25, you can take the Metra train to McCormick Placefrom the Millennium Park (at Michigan Avenue and Randolph Street)or Van Buren Street (at Michigan Avenue) downtown stations.Parking at McCormick Place WestParking is available adjacent to McCormick Place West in Lot A onMartin Luther King Drive. The parking rate is $19 for up to 16 hoursand $30 from 16 to 24 hours. There are no in-and-out fee options.AIRLINE TICKETS AND CAR RENTALSAssociation Travel Concepts is the official travel agency of the ACRand offers several time and cost saving options and services.Discounts – Ways You Can Save!• Five percent discount on applicable classes of service for ticketspurchased prior to the meeting on Delta and American Airlines.• Five percent discount on applicable classes of service for ticketspurchased more than 30 days prior to the meeting on UnitedAirlines.The above discounts apply for travel to O’Hare International Airport(ORD) and Midway International Airport (MDW) November 1 - 12,2011. Some restrictions apply.• ATC will search for the lowest available fare on any airline.• ATC will search for Zone Fares (region-to-region flat rates) andConsolidator and Net Fares which can reduce the cost of highprice tickets without a Saturday night stay.• ATC can provide discounted car rentals with Enterprise and Hertz.• Service fees apply. By booking your reservation online throughATC, service fees are discounted.ReservationsMake your reservation via ATC using one of the following options:• Web: www.atcmeetings.com/acr– Use the airfare search tool under “Search for Discount Flights”to start your search.– United and American discounts noted below are availablethrough the online booking tool.• E-mail: reservations@atcmeetings.com• Phone: (800) 458-9383• Fax: (858) 362-3153Visit My ACR at www.rheumatology.org/annual to plan your schedule and view up to date session, abstract and syllabi information.

54NOTE: Delta ticket discounts can only be obtained online at www.delta.com (be sure to enter the ID code listed below) or by calling anATC agent at the number listed above.If you prefer to use your own travel agency, airline or carrental agency discounts may apply if you use the followingidentification codes.Airline: Telephone: Identification Code:American (800) 433-1790 27N1ARUnited (800) 521-4041 510CKDelta/Northwest (800) 328-1111 NM7BPEnterprise (800) 593-0505 32H7476Hertz (800) 331-1600 CV#031C0016INTERNATIONAL TRAVELERSThe ACR is pleased to provide a forum where attendees can learnabout the latest advancements in the field of rheumatology. Wehope the following information will make your travel experience thebest it can be.International Invitation LetterIf you plan to apply for a temporary non-immigrant visa to attendthe annual meeting, you are advised to apply as soon as travel tothe United States is determined and no later than 3-4 months inadvance of your departure.After you have registered for the meeting, you will receive aconfirmation email that will include a link so you can download yourinvitation letter. Each letter will be customized and include yourpersonal information. The letter of invitation, though not requiredfor the visa application, may be a helpful supporting document andcan be presented to the consular officer during your visa interview.This letter does not guarantee your admittance into the U.S.Regrettably, the ACR cannot intervene with either U.S. embassiesabroad or with the U.S. State Department on behalf of any attendee.Visa Waiver ProgramThe Visa Waiver Program enables nationals of certain countries totravel to the United States for tourism or business for stays of 90days or less without obtaining a visa. For more information, go towww.travel.state.gov/visa.Travel Approval Required for Visa WaiverCountriesA valid Electronic System for TravelAuthorization (ESTA) approval is requiredfor all VWP to travel to the United States. The Department ofHomeland Security, ESTA, is a free, automated system used todetermine the eligibility of visitors to travel to the United Statesunder the VWP. It collects the same information as the paperI-94W form that VWP travelers fill out when traveling to the U.S.ESTA applications may be submitted at any time prior to travel.An ESTA authorization generally will be valid for up to two years.Authorizations will be valid for multiple entries into the U.S. TheDepartment of Homeland Security recommends that travelerssubmit an ESTA application as soon as they begin making travelplans. Learn more at https://esta.cbp.dhs.gov/esta.• Effective January 20, 2010, The Department of HomelandSecurity is transitioning to enforced compliance of the ESTArequirement for VWP travelers. Therefore, VWP travelerswho have not obtained approval through ESTA should expectto be denied boarding on any air carrier bound for the U.S.• Effective September 8, 2010, U.S. Customs and BorderProtection will charge $14 for all new or renewed ESTA.The fees include a $4 administrative fee and a $10 travelpromotion fee established by the Travel Promotion Act of2009. More information regarding this fee can be found atwww.cbp.gov.Tips for Successful Visa Applications• Include a letter of invitation. When possible, provide proofof professional scientific and/or educational status, societymembership and/or meeting registration.• Provide evidence that you intend to return to your country ofresidence. Therefore, you should provide proof of binding orsufficient ties to your home country or permanent residenceabroad. Visa applications are more likely to be successful if donein your home country.• Present your entire trip itinerary, including travel to any countriesother than the U.S. at the time of your visa application.• You must be able to qualify for a visa on their own merits underthe requirements of the Immigration and Nationality Act.International Group Travel PackagesThe official international travel provider for ACR 2011, CMRGlobal Group Services, provides full service group travel packagesfor individuals traveling from outside North America. Packagesinclude: hotel room, airport transfers in Chicago, baggagehandling at the hotel, daily American breakfast, local taxesand staff travel assistance. For more information, go towww.acr-cmrglobalgroupservices.com or acr@cmrglobalgroupservices.com.If you plan to apply for a temporary non-immigrant visa toattend the annual meeting, you are advised to apply as soonas travel to the United States is determined and no laterthan 3-4 months in advance of your departure.

egistration & preliminary programREGISTRATION AND HOUSING GUIDEMember Housing and Registration Opens:9:00 am ET, Wednesday, June 8Non-Member Housing and Registration Opens:9:00 am ET, Wednesday, June 22Three Easy Ways to Register and Make Hotel Reservations1.2.3.Online: www.rheumatology.org/annualMail:ACR Registration and Housing33 New Montgomery StreetSuite 1100San Francisco, CA 94105, USA Fax: (415) 293-5231(credit card payments only)PaymentFull payment is due at the time of registration. Faxed registrationsthat do not include payment will not be registered. Registrationsreceived after the “Early Bird” or “Advance” deadlines will becharged at the next highest rate. You will be contacted before thecharges are applied.Need Help?Contact the help line for questions about registration or housing.(800) 990-2446 (toll-free U.S. and Canada)(415) 979-2286 (international)Monday – Friday, 9:00 am – 9:00 pm ETMeet the Professor Sessions and WorkshopsYou can register for a Meet the Professor or Workshop session assoon as registration opens. We understand that you may select asession and later determine it conflicts with your favorite abstractsession, so you may exchange your registration up to 24 hoursprior to the session. You may also cancel your Meet the Professoror Workshop registration and receive a full refund if your requestis received by Tuesday, October 11. To purchase a ticket for Meetthe Professor or Workshop sessions, you must be registered for themeeting.Guided Poster ToursRegistration for poster tours will open in September. Although thetours are complimentary, registration is required. You will receive aticket with your meeting materials. Once you pick-up your ticket allyou will need to do is check-in at the poster tour desk 15 minutesprior to the start of your tour to receive your headset. Please notethat your reservation will be held only until 5 minutes prior to thestart of the tour. After this time, your reservationwill be released to standby attendees. Connectto My ACR at www.rheumatology/annual inSeptember for a list of tours.Are you registering multiple individuals?If you are registering for someone or onbehalf of multiple attendees, you are requiredto enter the actual contact information for each attendee.This will ensure that each attendee can access online meetingmaterials including the syllabi and SessionSelect. The ACR willnot accept your contact information for multiple attendees andwill not process the registration without the correct attendeeinformation. If you have a group of 10 or more see page 57.REGISTRATION CONFIRMATIONAttendees who pre-registered on or before Friday, October 21 willreceive a confirmation containing a barcode typically within 48 hoursof receipt of payment. If you do not receive your confirmation withinfive business days, please call (800) 990-2446 or (415) 979-2286.The barcode is your official documentation and must be presentedonsite to collect your badge, materials and tickets. You will alsobe sent a reminder confirmation approximately two weeks beforethe meeting. Registered attendees are required to pick-up theirregistration materials in person, unless registered as part of anofficial group through ACR group registration. Pick-up of meetingmaterials by a third party is not permitted.REGISTRATION CANCELLATIONSCancellations must be received in writing and received by Tuesday,October 11. No refunds will be issued after this date. Memberrefunds will be assessed a $50 processing fee; non-member refundswill be assessed a $100 processing fee. No fee will be assessed forguest cancellations. Send requests to ACR Registration and Housingat the address listed on this page or by e-mail to: acrreg@cmrus.com. Refunds will not be issued on site. Cancelled registrations arenon-transferable. All tickets purchased for the Opening Event at theField Museum of Natural History are non-refundable.REGISTRATION CATEGORIESACR or ARHP MemberIndividuals who have been elected to membership and have paiddues for the 2011 membership year or who are candidates to beelected to membership at the 2011 annual meeting.Non-MemberIndividuals who are not ACR or ARHP members. Save on registrationfees by becoming a member! See page 66 for more information.Member TraineeFellows-in-training who have been elected to membership and havepaid dues for 2011 or are candidates to be elected to membership atthe annual meeting.55Visit My ACR at www.rheumatology.org/annual to plan your schedule and view up to date session, abstract and syllabi information.

56Non-Member TraineeFellows-in-training who have not been elected to membership.These individuals must mail or fax a letter from their programdirector, chief of service or faculty advisor with their registrationform to be eligible for reduced fees.MasterACR members over the age of 65 who have been bestowed this titleby the ACR Board of Directors. The fee for the annual meeting iswaived. Fees are required for ticketed sessions e.g., pre-conferencecourses, Meet the Professor and Workshop sessions. Masters arerequired to pay a fee to attend the 2011 opening event.EmeritusMembers of the ACR or ARHP who have retired from active practiceor who are permanently disabled. These individuals must be namedEmertius members before registering to be eligible for reduced fees.They should submit a letter to the ACR Membership Departmentattesting to this change in work status and asking to be made anEmeritus member.Member ResidentMember residents are individuals who have finished medical schooland who are in training for their primary specialty. They must havebeen elected to membership and have paid dues for the 2011membership year or are candidates to be elected to membership atthe annual meeting,Non-member ResidentNon-member residents are individuals who have finished medicalschool and who are in training for their primary specialty, but arenot members of the ACR. These individuals must mail or fax a letterfrom their program director or chief of service, along with theirregistration form to be eligible for reduced fees.Member Medical or Other StudentIndividuals who are pursuing medical, graduate or undergraduatedegrees, have been elected to membership and have paid duesfor the 2011 membership year, or are candidates to be elected tomembership at the annual meeting.Non-Member Medical or Other StudentIndividuals who are pursuing medical, graduate or undergraduatedegrees, but who are not members of the ACR. These individualsmust mail or fax a letter from their program director or chiefof service, along with their registration form to be eligible forreduced fees.Fellows-in-Training from Developing CountriesComplimentary registration to the scientific session will be offered tofellows-in-training from developing countries. Developing countrieshave been determined by the World Bank (www.worldbank.org) listof countries with a gross national income of $6000 or less. Pleasevisit www.rheumatology.org/annual for a listing of eligible countries.In order to receive your complimentary registration, please mail orfax your registration form and include a letter from your programdirector, chief of service or faculty advisor.GuestsThis category is reserved for non-scientific attendees 18 years of ageand older. In order to be admitted to non-ticketed sessions and theexhibit hall (including the wine and cheese reception), non-scientificattendees must register as a guest. This category is not to be used byassociates in the medical profession. Guests are not eligible for CMEcredits or Certificates of Participation. Guests are required to pay anadditional fee to attend the 2011 opening event.ChildrenThis category is reserved for non-scientific attendees 17 years ofage or younger. For safety reasons, strollers are not permitted in theexhibit hall and all children must be accompanied by an adult. Onlyregistered attendees will be permitted into meeting rooms. You maymake arrangements for child care through KiddieCorp. See page 51for more information.HOTEL RESERVATIONSThe deadline for submitting housing requests is Friday, October7. Rooms are assigned in the order received. Room blocks sell outquickly and cannot be guaranteed. In order to increase your chancesof receiving your preferred hotel, reserve your room as soon aspossible. See the list of hotels on page 59 and the hotel reservationform on page 71.ConfirmationYou will receive an immediate confirmation, if you reserve yourhousing online. For requests by other methods, confirmations willbe sent via e-mail within 48 hours of receipt. After each new requestor change, an updated confirmation will be sent. Please review yourconfirmation for accuracy as soon as you receive it.GuaranteeAll reservations must be guaranteed with a credit card or checkmade payable to Convention Management Resources in the amountof $200 per guest room or $400 per suite. Convention ManagementResources will not charge your credit card when making yourreservation. However, some hotels may charge your card when yourreservation is sent to the hotel after September 24.

Fees will be processed upon receipt of registration. If therequired information is not provided by Friday, September 23,the requested group registration will not be processed and theindividual attendees may be required to register at the on-siterate. The ACR reserves the right to charge higher registrationfees for incomplete forms that are not received by the groupregistration deadline of Friday, September 23.Group registration requests received after Friday, September 23will:• only be accepted on a case-by-case basis, and are subject toavailability• be required to pay by credit card• be required to provide names and payment to ACRRegistration at time of registrationGroup registration is complimentary for organizations that arehoused in any official ACR hotel through ACR Housing. Anygroup electing not to do so will be assessed a $125 per attendeefee. There are no exceptions.On-site Groups (five or more attendees)To avoid lines at attendee registration, ACR will provide groupregistration services for any tour group leader or companywanting to register five or more individuals’ on site. A $125per attendee fee will be assessed to the group leader for thisservice. During peak hours on site, the group leader may berequired to schedule a pick-up time for badges and materials.Please note that it is the responsibility of the group leader topick up and distribute all materials to their group. ACR will notprovide or have staff available to assist in the transportation ofmaterials.Italian Pharmaceutical CompaniesACR will be working with CMR Global Group Services to collectall applications from Italian pharmaceutical companies andfile them with the appropriate Italian Health Ministry officials.Contact Mr. Angel Napolitano, Vice President – EuropeanDivision, CMR Global Group Services; Via Giacomo Trevis 88Sc.A int. 2; 00147 Rome, Italy.tel: +39 06.902.86.041; fax: +39 06.233.245.675; e-mail:napolitano@abtscs.com.58you’ll find a remarkable range of hoteloptions in the City of Big Shoulders!

egistration & preliminary programMAP AND HOTEL LIST• All rates are for single or double occupancy. Rates do not include 15.4% tax.• Complimentary in-room Wi-Fi will be provided by all hotels except forthe Hyatt Regency McCormick Place which charges $10–15 per night(depending on speed).• Complimentary shuttle service will be provided from ACR hotels — exceptfor the Hyatt Regency McCormick (No. 18) — during peak morning andafternoon hours. During non-peak times, a complimentary shuttle willoperate to/from several downtown locations.• Accessible transportation can be arranged in advance by contactingJillene Szostak at Chicago Travel Consultants at (773) 619-2274 orjszostak@ctcdmc.com.Official Hotels1. Amalfi Hotel Chicago ($209 king/one bed; $229 double/double – 2 beds)2. Chicago Essex Inn ($159)3. Chicago Marriott Downtown Magnificent Mile ($245)4. Courtyard by Marriott Chicago Downtown ($169)5. Doubletree Chicago Magnificent Mile ($175)6. Fairmont Hotel Millennium Park ($249)7. Hampton Inn & Suites Downtown River North ($165)8. Hampton Majestic Chicago Theater District ($189)9. Hard Rock Hotel Chicago ($239)* 10. Hilton Chicago: Co-Headquarter ($259; $309 Executive Level)11. Hilton Garden Inn Chicago Downtown Magnificent Mile ($165)5912. Homewood Suites by Hilton Downtown Chicago ($175)13. Hotel 71 ($199)14. Hotel Burnham ($229)15. Hotel Monaco ($219)16. Hotel Palomar ($229)17. Hyatt Regency Chicago ($245; $295 Executive Level)18. Hyatt Regency McCormick Place ($259)19. InterContinental Chicago ($249)20. JW Marriott ($255)* 21. Palmer House Hilton: Co-Headquarter ($245; $295 Executive Level)22. Renaissance Blackstone Chicago Hotel ($249)23. Renaissance Chicago ($249)24. Residence Inn Chicago River North ($175)25. Sax Chicago ($209)26. Sheraton Chicago Hotel & Towers ($249; $289 Premium; $329 Club Level)27. Silversmith Hotel & Suites ($189)28. Springhill Suites by Marriott Downtown River North ($165)29. Swissotel Chicago ($225)30. Westin Chicago River North ($249)Visit My ACR at www.rheumatology.org/annual to plan your schedule and view up to date session, abstract and syllabi information.

meet the professors & workshopsMeet the Professor and Workshop sessions are listed below inalphabetical order by session title. To view individual Meet theProfessor and Workshop session objectives, visit My ACR atwww.rheumatology/annual.Each Meet the Professor session is limited to 35 attendees.Workshop sessions are limited to 24 attendees. Beverages areincluded with these sessions.60Meet the ProfessorSAdult Inflammatory MyopathyMary E. Cronin, MDSun., 12:45 - 2:15 PM (011)Mon., 4:30 - 6:00 PM (051)Ankylosing Spondylitis: 2011 UpdateDesiree M. Van Der Heijde, MD, PhDSun., 12:45 - 2:15 PM (012)Tues., 12:45 - 2:15 PM (071)Ankylosing Spondylitis: Disease ModificationJoachim Sieper, MDTues., 7:45 - 9:15 AM (061)Antiphospholipid SyndromeGraham R. V. Hughes, MDMon., 7:45 - 9:15 AM (031)Tues., 7:45 - 9:15 AM (062)F Basic Immunology for Clinical RheumatologistsAnthony Rosen, MDMon., 12:45 - 2:15 PM (041)Tues., 12:45 - 2:15 PM (072)Behçet’s DiseaseHasan Yazici, MDSun., 7:45 - 9:15 AM (001)Central Nervous System VasculitisRula Hajj-Ali, MDMon., 4:30 - 6:00 PM (052)Controversies in Sjögren’s SyndromeAlan N. Baer, MDSun., 7:45 - 9:15 AM (002)Mon., 4:30 - 6:00 PM (053)Crystal: Management of GoutNaomi Schlesinger, MDSun., 4:30 - 6:00 PM (021)Crystal: Management of GoutMichael A. Becker, MDMon., 7:45 - 9:15 AM (032)Tues., 7:45 - 9:15 AM (063)Crystal: PseudogoutGeraldine M. McCarthy, MDMon., 12:45 - 2:15 PM (042)F Cutaneous VasculitisNicole Fett, MDSun., 12:45 - 2:15 PM (013)Dermatological Manifestations of Rheumatic DiseasesNicole Fett, MDSun., 4:30 - 6:00 PM (022)Tues., 4:30 - 6:00 PM (081)PM Difficult Patient InteractionsDennis J. Boyle, MDTues., 7:45 - 9:15 AM (064)Effective Use of TechnologyWilliam M. McClatchey, MDTues., 4:30 - 6:00 PM (082)PM FibromyalgiaManuel Martinez-Lavin, MDMon., 4:30 - 6:00 PM (054)PM Fibromyalgia and DysautonomiaManuel Martinez-Lavin, MDTues., 12:45 - 2:15 PM (073)Immunodeficiency SyndromesAlton Melton, MDSun., 4:30 - 6:00 PM (023)Inflammatory Eye Disease/UveitisJames T. Rosenbaum, MDMon., 4:30 - 6:00 PM (055)Myopathy: Issues in Diagnosis and TreatmentMark F. Gourley, MDSun., 12:45 - 2:15 PM (014)Tues., 12:45 - 2:15 PM (074)Osteoarthritis: Update 2011Richard F. Loeser, MDMon., 7:45 - 9:15 AM (033)Tues., 7:45 - 9:15 AM (065)

egistration & preliminary programOsteoporosis: Applying FRAX MethodologyThomas P. Olenginski, MDMon., 12:45 - 2:15 PM (043)Osteoporosis: Novel TreatmentsMichael J. Maricic, MDSun., 12:45 - 2:15 PM (015)PM Pain: Evaluation and Treatment of Back PainDavid G. Borenstein, MDSun., 7:45 - 9:15 AM (003)Tues., 7:45 - 9:15 AM (066)p Pediatric Rheumatology for Adult RheumatologistsPeter A. Nigrovic, MDMon., 7:45 - 9:15 AM (034)p Pediatric Systemic LupusMara L. Becker, MDMon., 4:30 - 6:00 PM (056)p Pediatrics: DermatomyositisAdam Huber, MDSun., 4:30 - 6:00 PM (024)p Pediatrics: Difficult to Treat Juvenile Idiopathic ArthritisMurray H. Passo, MDSun., 7:45 - 9:15 AM (004)p Pediatrics: Juvenile Idiopathic Arthritis for AdultRheumatologistsMara L. Becker, MDMon., 7:45 - 9:15 AM (035)p PM Pediatrics: Periodic Fevers in ChildrenPolly J. Ferguson, MDMon., 12:45 - 2:15 PM (044)p Pediatrics: Spondyloarthritis in ChildrenShirley Tse, MDMon., 7:45 - 9:15 AM (036)Polymyalgia RheumaticaBhaskar Dasgupta, MDSun., 12:45 - 2:15 PM (016)Pregnancy in Rheumatic DiseasesMegan E. B. Clowse, MD, MPHSun., 12:45 - 2:15 PM (017)Tues., 7:45 - 9:15 AM (067)Psoriatic ArthritisArthur Kavanaugh, MDSun., 4:30 - 6:00 PM (025)Psoriatic ArthritisElaine Husni, MD, MPHMon., 7:45 - 9:15 AM (037)Tues., 4:30 - 6:00 PM (083)Pulmonary Hypertension in the Rheumatic DiseasesJames R. Seibold, MDSun., 7:45 - 9:15 AM (005)Pulmonary Manifestations of Rheumatic DiseasePaul F. Dellaripa, MDMon., 12:45 - 2:15 PM (045)Tues., 12:45 - 2:15 PM (075)Raynaud’s and Digital IschemiaJanet E. Pope, MD, MPHMon., 12:45 - 2:15 PM (046)Tues., 4:30 - 6:00 PM (084)Reactive Arthritis: An UpdateAtul A. Deodhar, MD, MRCPMon., 4:30 - 6:00 PM (057)Rheumatoid Arthritis: Biological AgentsLarry W. Moreland, MDMon., 4:30 - 6:00 PM (058)Tues., 4:30 - 6:00 PM (085)Rheumatoid Arthritis: Challenging CasesJonathan Kay, MDSun., 7:45 - 9:15 AM (006)Tues., 12:45 - 2:15 PM (076)Rheumatoid Arthritis: Difficult CasesStanley B. Cohen, MDMon., 7:45 - 9:15 AM (038)Rheumatoid Arthritis: Difficult Rheumatoid ArthritisNancy A. Shadick, MD, MPHSun., 7:45 - 9:15 AM (007)Rheumatoid Arthritis: Early Rheumatoid ArthritisJames R. O’Dell, MDSun., 7:45 - 9:15 AM (008)Tues., 7:45 - 9:15 AM (068)PS Rheumatoid Arthritis: Outcome Measures in Clinical PracticeMartin J. Bergman, MDSun., 4:30 - 6:00 PM (026)PS Rheumatoid Arthritis: Safety of Novel TherapiesDaniel Hal Solomon, MD, MPHF Mon., 12:45 - 2:15 PM (047)Tues., 4:30 - 6:00 PM (086)61Visit My ACR at www.rheumatology.org/annual to plan your schedule and view up to date session, abstract and syllabi information.

meet the professors & workshops62F Rheumatology Practice 101: Starting Out in Practice for TheGraduating FellowMichael J. Maricic, MDTues., 4:30 - 6:00 PM (087)Scleroderma MimicsLaura K. Hummers, MD, ScMMon., 12:45 - 2:15 PM (048)Scleroderma: Systemic SclerosisMichael R. York, MDMon., 7:45 - 9:15 AM (040)Scleroderma: Systemic SclerosisChristopher P. Denton, MD, PhDMon., 7:45 - 9:15 AM (039)Tues., 7:45 - 9:15 AM (069)Spondyloarthropathy: An UpdateDaniel O. Clegg, MDSun., 7:45 - 9:15 AM (009)Systemic Arthritis and Still’s DiseaseRayfel Schneider, MBBChSun., 4:30 - 6:00 PM (027)Systemic Lupus Erythematosus: Central Nervous SystemF. Jorge Sanchez-Guerrero, MDSun., 4:30 - 6:00 PM (028)Tues., 12:45 - 2:15 PM (077)Systemic Lupus Erythematosus: Difficult to Treat Systemic LupusErythematosusElena M. Massarotti, MDSun., 12:45 - 2:15 PM (018)Tues., 12:45 - 2:15 PM (078)Systemic Lupus Erythematosus: Lupus NephritisFrederic A. Houssiau, MD, PhDSun., 7:45 - 9:15 AM (010)Tues., 4:30 - 6:00 PM (088)Systemic Lupus Erythematosus: Novel TreatmentsMary Anne Dooley, MD, MPHSun., 12:45 - 2:15 PM (019)Systemic Lupus Erythematosus: Novel TreatmentsRobert G. Lahita, MD, PhDMon., 4:30 - 6:00 PM (059)Temporal ArteritisGene G. Hunder, MDSun., 4:30 - 6:00 PM (029)Tues., 12:45 - 2:15 PM (079)Vaccinations for Patients on Biologic TherapiesClifton O. Bingham, MDMon., 12:45 - 2:15 PM (049)Tues., 4:30 - 6:00 PM (089)Vasculitis MimicsJohn H. Stone, MD, MPHSun., 4:30 - 6:00 PM (030)Vasculitis: An UpdatePaul A. Monach, MD, PhDMon., 4:30 - 6:00 PM (060)Tues., 12:45 - 2:15 PM (080)Vasculitis: UpdatePeter A. Merkel, MD, MPHMon., 12:45 - 2:15 PM (050)Tues., 7:45 - 9:15 AM (070)Vitamin D and Bone HealthKaren E. Hansen, MD, MSSun., 12:45 - 2:15 PM (020)WORKSHOPSAdult Musculoskeletal Lower ExaminationsArthur M. Mandelin, MD, PhDTues., 7:45 - 9:45 AM (228)Adult Musculoskeletal Upper ExaminationsArthur M. Mandelin, MD, PhDSun., 4:00 - 6:00 PM (212)Basic Statistical Concepts for the Medical ResearcherDorothy D. Dunlop, PhDJungwha “Julia” Lee, MD, PhDMon., 1:15 - 3:15 PM (221)Dermatopathology of Rheumatic DiseasesLynne J. Goldberg, MDSun., 7:45 - 9:45 AM (201)Sun., 1:15 - 3:15 PM (209)Designing a Website for Your PracticePeter J. Embi, MD, MSSun., 10:30 AM - 12:30 PM (204)Diagnostic Errors in Rheumatology: Why They Happen and How WeCan Avoid ThemJoan Marie Von Feldt, MD, MS, EdAlexis Ogdie, MDMon., 1:15 - 3:15 PM (222)

egistration & preliminary programGetting Electronic Health Record RightSalahuddin Kazi, MDMon., 1:15 - 3:15 PM (223)Histopathology of VasculitisAllen Burke, MDJonathan Heath, MDTues., 10:30 AM - 12:30 PM (232)Tues., 1:15 - 3:15 PM (235)F Joint Injection TechniquesAtul A. Deodhar, MD, MRCPKenneth S. O’Rourke, MDSun., 10:30 AM - 12:30 PM (205)Tues., 10:30 AM - 12:30 PM (233)Joint Injections (Knee and Ankle Prosthetics)Gregory C. Gardner, MDMon., 7:45 - 9:45 AM (215)Joint Injections (Shoulder and Wrist Prosthetics)Gregory C. Gardner, MDMon., 4:00 - 6:00 PM (225)Knee Braces and Foot Orthosis for Knee OsteoarthritisHoward J. Hillstrom, PhDKelly D. Krohn, MDMon., 4:00 - 6:00 PM (226)Muscle Involvement in Rheumatic DiseasesSakir Humayun Gultekin, MDTues., 1:15 - 3:15 PM (236)Musculoskeletal Exam Skills IGeorge V. Lawry, MDPaul C. Utrie, MDMon., 10:30 AM - 12:30 PM (218)Musculoskeletal Exam Skills IIGeorge V. Lawry, MDPaul C. Utrie, MDTues., 7:45 - 9:45 AM (229)Musculoskeletal Exam Skills IIIGeorge V. Lawry, MDPaul C. Utrie, MDTues., 10:30 AM - 12:30 PM (234)F Musculoskeletal ImagingWilliam Morrison, MDTues., 1:15 - 3:15 PM (237)F Musculoskeletal Ultrasonography: BasicJanak R. Goyal, MDGurjit S. Kaeley, MBBS, MRCPSun., 7:45 - 9:45 AM (202)F Musculoskeletal UltrasoundEugene Y. Kissin, MDSun., 4:00 - 6:00 PM (213)Mon., 7:45 - 9:45 AM (216)Osteoporosis: Interpreting Dual Energy X-ray Absorptiometry andClinical Risk Factors: The New Fracture Risk Assessment AlgorithmStuart L. Silverman, MDSun., 7:45 - 9:45 AM (203)Mon., 10:30 AM - 12:30 PM (219)Patient Questionnaires to Monitor Status and DocumentImprovement in Standard Care: Practical ConsiderationsTheodore Pincus, MDTues., 4:00 - 6:00 PM (238)Peripheral Magnetic Resonance Imaging in Clinical RheumatologyEwa Olech, MDOrrin M. Troum, MDSun., 1:15 - 3:15 PM (210)Mon., 1:15 - 3:15 PM (224)Peripheral Magnetic Resonance Imaging in Rheumatology PracticePhilip G. Conaghan, MD, PhDMikkel Ostergaard, MD, PhD, DMScSun., 10:30 AM - 12:30 PM (206)Tues., 4:00 - 6:00 PM (239)Physical Examination Skills for Improved Detection of Synovitis andCervical Thoracolumbar DisordersEd C. Keystone, MDSun., 10:30 AM - 12:30 PM (207)PowerPoint/Excel/GraphicsMaarten Boers, MD, PhD, MScTues., 4:00 - 6:00 PM (240)Renal Histopathology in Systemic Lupus Erythematosus andVasculitisMegan Troxell, MDSun., 4:00 - 6:00 PM (214)Mon., 7:45 - 9:45 AM (217)F Rheumatology Physical Examination of Lower Extremity andLumbosacral Spine: Anatomical CorrelatesRobert A. Kalish, MDPablo Villasenor Ovies, MDSun., 1:15 - 3:15 PM (211)63Visit My ACR at www.rheumatology.org/annual to plan your schedule and view up to date session, abstract and syllabi information.

meet the professors & workshopsF Rheumatology Physical Examination of Upper Extremityand Cervical Spine: Anatomical CorrelatesRobert A. Kalish, MDPablo Villaseor-Ovies, MDTues., 7:45 - 9:45 AM (230)Synovial Fluid Analysis and Crystal IdentificationBrian F. Mandell, MD, PhDLan X. Chen, MD, PhDGilda M. Clayburne, MLTSun., 10:30 AM - 12:30 PM (208)F Mon., 10:30 AM - 12:30 PM (220)Tues., 7:45 - 9:45 AM (231)F Systemic Sclerosis: How to Perform Skin ScoresDaniel E. Furst, MDMon., 4:00 - 6:00 PM (227)64

Opportunities for InteractionAn Intimate Educational Experience AwaitsSecure your Seat in a Meet the Professor or Workshop SessionThese classroom-styled sessions offer opportunities for comprehensive instruction andin-depth discussion with respected professionals who have expertise in a special area.Choose from over 100 Meet the Professor and Workshops sessions.Spaceis limited;sign up today!See page 60 formore information.Study Groups – Professional Networking OpportunitiesTake advantage of these unique social forums, designed to bring together attendees witha common interest in a single disease, a group of related disorders or a specialized fieldof study.Choose from over 30 different study groups on a variety of topics, offered duringtwo convenient time slots: Monday, November 7 from 6:45 – 8:00 pm, and Tuesday,November 8 from 1:00 – 2:00 pm.For study group details, visit My ACR at www.rheumatology.org/annual.Study Groups are free and open to all attendees.This is your opportunity to connect withcolleagues, make contacts and exchange ideas.

Max Out Your Membership & Save Hundreds!Would you like discounted registration and priority housingfor the 2011 ACR/ARHP Annual Scientific Meeting inChicago? Then make sure your ACR membership is currentand up-to-date!Member registration opens June 8 – two weeks before nonmemberscan register.Priority Registration & Housing AccessPriority registration gives members preference for populareducational sessions, Meet the Professors, the openingreception, and other limited-space events.Members also have priority access to housing beginning June8. Members can reserve hotel space without registering forthe meeting, but if your membership isn’t current, you won’thave access.How Much Can Early Birds Save?Register by Sept. 9, 2011 and you’ll enjoy the lowest ratespossible:Annual Meeting RegistrationMembers Pay $395 Non-Members Pay $585Save $190Meet the ProfessorMembers Pay $50 Non-Members Pay $75Save $25Basic Research ConferenceMembers Pay $185 Non-Members Pay $275Save $90Review CourseMembers Pay $195 Non-Members Pay $290Save $95Musculoskeletal Ultrasound CourseMembers Pay $970 Non-Members Pay $1350Save $380Membership Questions?Send an email to the membership department atmembership@rheumatology.org and ask about yourmembership status. We’ll send a prompt reply.As a registered scientific attendee, you willreceive FREE access to over 200 hours ofonline annual meeting content, includingabstracts – over $500 of added value!

individual registrationform• Go to www.rheumatology.org/annual for quick and easy registration online.• If mailing or faxing registration forms, be sure to include all four pages.• This form is for individual registration only. For groups of 10 or more, contact ACR at acrgroups@cmrus.com.MAIL: ACR Registration and Housing33 New Montgomery Street, Suite 1100San Francisco, CA 94105FAX: (415) 293-5231QUESTIONS: Phone (Mon-Fri, 9:00AM-9:00PM ET)(800) 990-2446 (US & Canada)(415) 979-2286 (International)E-Mail: acrreg@cmrus.com1. PERSONAL INFORMATION (please print or type clearly) Individual registrant’s information is required.member id (see mailing label):lastname:firstname:middleinitial:nickname(for badge):birth date*(dd/mm/year):institution:mailingaddress:telephone:mobile:fax:e-mail:emergency contact: phone: relationship:*A birth date is requested for international attendees only.qCheck here if you require special assistant to fully participate in the meeting (please attach a separate sheet to indicate needs).2. REGISTRATION FEES — PRE-CONFERENCE COURSES FEESEarly Birdby sept. 9Advanceby oct. 21OnsiteACR/ABIM Maintenance of Certification Learning Session -Friday, Nov. 4Member q $110 q $140 q $160Non-Member q $160 q $210 q $240Member Trainee q $60 q $75 q $85Non-Member Trainee* q $85 q $110 q $125Master q $60 q $75 q $85Emeritus q $60 q $75 q $85Member Resident/Medical Student q no fee q no fee q no feeNon-Member Resident/Medical Student* q no fee q no fee q no feeACR Basic Research Conference - Friday & Saturday, Nov. 4 & 5Member q $185 q $260 q $300Non-Member q $275 q $395 q $450Member Trainee q $120 q $145 q $165Non-Member Trainee* q $175 q $215 q $250Master q $100 q $135 q $155Emeritus q $100 q $135 q $155Member Resident/Medical Student q no fee q no fee q no feeNon-Member Resident/Medical Student* q no fee q no fee q no feeACR Musculoskeletal Ultrasound Course for Rheumatologists -Friday & Saturday, Nov. 4 & 5Member q $980 q $1325 q $1520Non-Member q $1365 q $1840 q $2120ACR Certified Rheumatology Coder Course (Fri., Nov. 4) and Exam(Sat., Nov. 5)Member (course & exam) q $400 q $450 q $500Non-Member (course & exam) q $450 q $500 q $550Member (course only) q $250 q $275 q $300Non-Member (course only) q $300 q $325 q $350Early Birdby sept. 9Advanceby oct. 21OnsiteACR Clinical Research Conference – Saturday, Nov. 5Member q $135 q $210 q $240Non-Member q $245 q $350 q $405Member Trainee q $95 q $120 q $140Non-Member Trainee* q $125 q $220 q $255Master q $95 q $120 q $140Emeritus q $95 q $120 q $140Member Resident/Medical Student q no fee q no fee q no feeNon-Member Resident/Medical Student* q no fee q no fee q no feeACR Review Course – Saturday, Nov. 5Member q $195 q $295 q $340Non-Member q $290 q $450 q $520Member Trainee q $135 q $185 q $215Non-Member Trainee* q $195 q $270 q $310Master q $135 q $185 q $215Emeritus q $135 q $185 q $215Member Resident/Medical Student q no fee q no fee q no feeNon-Member Resident/Medical Student* q no fee q no fee q no feeARHP Clinical Focus Course – Saturday, Nov. 5Member q $185 q $235 q $270Non-Member q $275 q $360 q $415Emeritus q $135 q $185 q $215Student Member q no fee q no fee q no feeStudent Non-Member* q $85 q $90 q $10567*Non-member trainees, residents and students must include a letter from their program director, chief of service or faculty advisor to be eligible for reduced fees.

Registration form – Page 2 of 4Last Name____________________________________First Name____________________________________ Middle Initial_____________3. REGISTRATION FEES - SCIENTIFIC SESSIONSEarly Birdby sept. 9Advanceby oct. 21OnsiteEarly Birdby sept. 9Advanceby oct. 21OnsiteACR Scientific Meeting - Saturday, Nov. 5 — Wednesday, Nov. 9Member q $395 q $505 q $580Non-Member q $585 q $760 q $875Member Trainee q $200 q $255 q $295Non-Member Trainee* q $295 q $385 q $445Master q no fee q no fee q no feeEmeritus q $200 q $255 q $295Member Resident/Medical Student q no fee q no fee q no feeNon-Member Resident/Medical Student* q no fee q no fee q no feeARHP Scientific Meeting - Saturday, Nov. 5 — Wednesday, Nov. 9Member q $285 q $405 q $465Non-Member q $445 q $620 q $715Emeritus q $200 q $255 q $295Student Member q no fee q no fee q no feeStudent Non-Member* q $185 q $190 q $220*Non-member trainees, residents and students must include a letter fromtheir program director, chief of service or faculty advisor to be eligiblefor reduced fees.4. MEET THE PROFESSOR AND WORKSHOP FEESMeet the ProfessorMember - $50 Non-Member - $75WorkshopsMember - $100 Non-Member - $150Select up to three choices in each time period. (Use the 3-digit codes on pages 60-64.)1st Choice 2nd Choice 3rd Choice1st Choice 2nd Choice 3rd ChoiceSUNDAY, NOVEMBER 6Professors (001-010)7:45 – 9:15 AMWorkshops (209-211)1:15 – 3:15 PM68Workshops (201-203)7:45 – 9:45 AMWorkshops (212-214)4:00 – 6:00 PMWorkshops (204-208)10:30 AM – 12:30 PMProfessors (021-030)4:30 – 6:00 PMProfessors (011-020)12:45 – 2:15 PMMONDAY, NOVEMBER 7Professors (031-040)7:45 – 9:15 AMWorkshops (221-224)1:15 – 3:15 PMWorkshops (215-217)7:45 – 9:45 AMWorkshops (225-227)4:00 – 6:00 PMWorkshops (218-220)10:30 AM – 12:30 PMProfessors (051-060)4:30 – 6:30 PMProfessors (041-050)12:45 – 2:15 PMTUESDAY, NOVEMBER 8Professors (061-070)7:45 – 9:15 AMWorkshops (235-237)1:15 – 3:15 PMWorkshops (228-231)7:45 – 9:45 AMWorkshops (238-240)4:00 – 6:00 PMWorkshops (232-234)10:30 AM – 12:30 PMProfessors (081-089)4:30 – 6:30 PMProfessors (071-080)12:45 – 2:15 PM

Registration form – Page 3 of 4Last Name____________________________________First Name____________________________________ Middle Initial_____________5. ADDITIONAL ITEMSAbstract Supplement (please check one): q I wish to receive the printed abstract supplement onsite. (2011 supplement will weigh approx. 8 lbs –orders received after Sept 9 are subject to availability)q I wish to receive a flash drive of the abstract supplement onsite.q No thanks! I will access the abstract supplement online.Opening Event – Field Museum of Natural History (Saturday, November 5) ______ (quantity) at $40 each = $________Tickets for the opening event at the Field Museum may be purchased without registering as a spouse or guest.Shuttle Bus Pass (for those who are not staying in ACR contracted hotels) ______ (quantity) at $40 each = $________6. GUEST REGISTRATION (18 years of age and older)______ (quantity) at $90 each = $________lastname:lastname:firstname:firstname:middleinitial:middleinitial:7. QUICK QUESTION DATAAre you board certified in rheumatology (physicians only):q Yes (see next question) q NoIf yes, when did you pass the rheumatology boards:q Before 1991 q 1991 - 1996q 1997 - 2002 q 2003 - 2008q 2009 - 2011Which of the following devices do you use (check all that apply):q Blackberryq Kindleq iPhoneq Nookq Androidq iPadq Cellphone with no email or Internet capabilityq Other (specify) __________________________8. PAYMENT INFORMATIONHow much influence do you have when selecting/purchasing equipmentand supplies utilized in your work environment?q Key decision makerq Research options and make recommendation to the key decision makerq I am not involved in these types of decisionsIs the ACR/ARHP annual meeting the primary educational meeting you attend:q Yesq No. What meeting is your primary educational meeting:__________________________________________________________________________________________________________________________________________________________________________________________69Full payment is due at time of registration. Faxed forms that do not include payment will not be processed. Registrations received after the"Early Bird" or "Advance" deadlines will be charged at the highest rate.Pre-Conference Course Fees:Scientific Meeting Fees:Spouse/Guest Fees:$_____________________________$_____________________________$_____________________________Opening Reception Tickets: $_____________________________Shuttle Bus Passes:$_____________________________total registration fees $_ _____________________q enclosed is check #_________ in the amount of $ ___________________ made payable to the american college of rheumatology(in u.s. funds only and drawn on a u.s. bank)q charge $ ____________________ to the following credit card:Visa MasterCard American Express Diners Clubcredit card numberexpiration datename as it appears on cardcardholder signature

Registration form – Page 4 of 4Last Name____________________________________First Name____________________________________ Middle Initial_____________9. MEET THE PROFESSOR and WORKSHOP PAYMENTFees for Meet the Professor sessions and Workshops can be paid by credit card only.TOTAL Meet the Professor / Workshop Fees: $__________________ Maximum number of sessions you wish to attend and for which you wish to be charged.q use same credit card as listed aboveq charge $ ____________________ to the following credit card:Visa MasterCard American Express Diners Clubcredit card numberexpiration datename as it appears on cardcardholder signature70

housingformContact Information (please print or type clearly)lastname:firstname:middleinitial:institution:city:phone:state/province:mobile:mailingaddress:country:fax:zip code/postal code:e-mail:Hotel Preferences (See Hotel List on page 59 and be sure to indicate at least six choices)Hotel requests will be honored on a first-come, first-served space-available basis. Submit your request as soon as possible to increase your chances of receivingone of your choices.1st choice_________________________________________________________ 4th choice_ _______________________________________________2nd choice_________________________________________________________ 5th choice_ _______________________________________________3rd choice_________________________________________________________ 6th choice_ _______________________________________________Room Occupant(s):last name: first name: arrival date: departure date:primary occupant:2nd occupant:3rd occupant:Room TypeRoom type: (Bed type, non-smoking and other preferences will be on a request basis only. Information is forwarded to the hotel for their consideration.)71Single (1 bed/1 person) Double (1 bed/2 persons) 2 Doubles (2 beds/2 persons) Suite (an ACR/ARHP Housing consultant will contact you)Smoking Non-Smoking OtherSpecial Needs (please specify):Guarantee Information (no reservation will be processed without a guarantee)Each reservation must be guaranteed with a credit card or a check (in U.S. funds) in the amount of $200 per room or $400 per suite. It is the hotel’s discretion tocharge the credit card listed below for guarantee. If you do not cancel your reservation or do not check-in on your confirmed day of arrival. No charges will be madeby ACR Housing.enclosed is check #_______________ for $________________ made payable to convention management resources, in u.s. funds.(reservations made by check deposit will not be confirmed until check payment is received)guarantee to the following credit card: Visa MasterCard American Expresscredit card numberexpiration datecardholder signaturecardholder name as it appears on credit cardCancellation PolicyAll reservations must be cancelled 72 hours prior to arrival to avoid any penalty charges. If you do not cancel your reservation at least 72 hoursnotice of your arrival date or fail to arrive on your confirmed date, your credit card will be charged in the amount of one night’s room rate plus taxand/or your deposit will be forfeited. Your reservation will also be cancelled for the remainder of your stay.Return this form byOctober 7, 2011ACR Housing and Registration; CMR; 33 New Montgomery Street, Suite 1100, San Francisco, CA 94105TEL: (800) 990-2446 or (415) 979-2286, 9:00 am – 9:00 pm et; FAX: (415) 293-5231 (credit card guarantees only)

2 0 1 1 A C R / A R H Pcall for abstractsSubmission Site is Now Open!to the premier meeting in rheumatologyDon’t miss the opportunity to be a part of the premier rheumatology scientificprogram! Submit an abstract today at www.rheumatology.org/annual.Abstract Submission Deadline: Tuesday, June 28 at Noon ETAbstract DeadlinesACR/ARHP abstract submission site opens ..................................Monday, May 2ACR/ARHP abstract submission site closes ..................................Tuesday, June 28ACR Late-breaking abstract submission site opens ........................Monday, September 19ACR Late-breaking abstract submission site closes ........................Tuesday, October 11GO! Join us in Chicago, November 4-9, for the 2011 ACR/ARHP Annual Scientific Meeting.Abstract submission guidelines and instructions are available at www.rheumatology.org/annual.

ACTEMRA ® (tocilizumab)Injection, for the intravenous infusionThis is a brief summary. Before prescribing, please refer to the full Prescribing Information.WARNING: RISK OF SERIOUS INFECTIONSPatients treated with ACTEMRA are at increased risk for developing serious infections that may lead to hospitalizationor death [see Warnings and Precautions, Adverse Reactions]. Most patients who developed these infections were takingconcomitant immunosuppressants such as methotrexate or corticosteroids.If a serious infection develops, interrupt ACTEMRA until the infection is controlled.Reported infections include:• Active tuberculosis, which may present with pulmonary or extrapulmonary disease. Patients should be tested forlatent tuberculosis before ACTEMRA use and during therapy. Treatment for latent infection should be initiated priorto ACTEMRA use.• Invasive fungal infections, including candidiasis, aspergillosis, and pneumocystis. Patients with invasive fungalinfections may present with disseminated, rather than localized, disease.• Bacterial, viral and other infections due to opportunistic pathogens.The risks and benefits of treatment with ACTEMRA should be carefully considered prior to initiating therapy in patientswith chronic or recurrent infection.Patients should be closely monitored for the development of signs and symptoms of infection during and aftertreatment with ACTEMRA, including the possible development of tuberculosis in patients who tested negative for latenttuberculosis infection prior to initiating therapy [see Warnings and Precautions].INDICATIONS AND USAGEACTEMRA ® (tocilizumab) is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritiswho have had an inadequate response to one or more TNF antagonist therapies.DOSAGE AND ADMINISTRATIONACTEMRA may be used as monotherapy or concomitantly with methotrexate or other DMARDs. The recommended dose ofACTEMRA for adult patients given once every 4 weeks as a 60-minute single intravenous drip infusion is:Recommended Adult Dosage Every 4 WeeksPatients who have had an inadequate responseto one or more TNF antagonistsWhen used in combination with DMARDs or as monotherapy the recommendedstarting dose is 4 mg per kg followed by an increase to 8 mg per kg based onclinical response.• Reduction of dose from 8 mg per kg to 4 mg per kg is recommended for management of certain dose-related laboratorychanges including elevated liver enzymes, neutropenia, and thrombocytopenia• Doses exceeding 800 mg per infusion are not recommended in RA patientsCONTRAINDICATIONSACTEMRA should not be administered to patients with known hypersensitivity to ACTEMRA [see Warnings and Precautions].WARNINGS AND PRECAUTIONSSerious InfectionsSerious and sometimes fatal infections due to bacterial, mycobacterial, invasive fungal, viral, protozoal, or other opportunisticpathogens have been reported in patients receiving immunosuppressive agents including ACTEMRA for rheumatoid arthritis. Themost common serious infections included pneumonia, urinary tract infection, cellulitis, herpes zoster, gastroenteritis, diverticulitis,sepsis and bacterial arthritis [see Adverse Reactions]. Among opportunistic infections, tuberculosis, cryptococcus, aspergillosis,candidiasis, and pneumocystosis were reported with ACTEMRA. Other serious infections, not reported in clinical studies, mayalso occur (eg, histoplasmosis, coccidioidomycosis, listeriosis). Patients have presented with disseminated rather than localizeddisease, and were often taking concomitant immunosuppressants such as methotrexate or corticosteroids which in addition torheumatoid arthritis may predispose them to infections.ACTEMRA should not be administered in patients with an active infection, including localized infections. The risks and benefitsof treatment should be considered prior to initiating ACTEMRA in patients:• with chronic or recurrent infection• who have been exposed to tuberculosis• with a history of serious or an opportunistic infection• who have resided or traveled in areas of endemic tuberculosis or endemic mycoses• with underlying conditions that may predispose them to infectionPatients should be closely monitored for the development of signs and symptoms of infection during and after treatment withACTEMRA, as signs and symptoms of acute inflammation may be lessened due to suppression of the acute phase reactants[see Adverse Reactions and Patient Counseling Information].ACTEMRA should be interrupted if a patient develops a serious infection, an opportunistic infection, or sepsis. A patient who developsa new infection during treatment with ACTEMRA should undergo a prompt and complete diagnostic workup appropriate for animmunocompromised patient, appropriate antimicrobial therapy should be initiated, and the patient should be closely monitored.TuberculosisPatients should be evaluated for tuberculosis risk factors and tested for latent infection prior to initiating ACTEMRA.Anti-tuberculosis therapy should also be considered prior to initiation of ACTEMRA in patients with a past history of latent or activetuberculosis in whom an adequate course of treatment cannot be confirmed, and for patients with a negative test for latenttuberculosis but having risk factors for tuberculosis infection. Consultation with a physician with expertise in the treatment oftuberculosis is recommended to aid in the decision whether initiating anti-tuberculosis therapy is appropriate for an individualpatient.Patients should be closely monitored for the development of signs and symptoms of tuberculosis including patients who testednegative for latent tuberculosis infection prior to initiating therapy.It is recommended that patients be screened for latent tuberculosis infection prior to starting ACTEMRA. The incidence oftuberculosis in worldwide clinical development programs is 0.1%. Patients with latent tuberculosis should be treated with standardantimycobacterial therapy before initiating ACTEMRA.Viral ReactivationViral reactivation has been reported with immunosuppressive biologic therapies and cases of herpes zoster exacerbation wereobserved in clinical studies with ACTEMRA. No cases of Hepatitis B reactivation were observed in the trials; however patients whoscreened positive for hepatitis were excluded.Gastrointestinal Perforations Events of gastrointestinal perforation have been reported in clinical trials, primarily as complicationsof diverticulitis. ACTEMRA should be used with caution in patients who may be at increased risk for gastrointestinal perforation.Patients presenting with new-onset abdominal symptoms should be evaluated promptly for early identification of gastrointestinalperforation [see Adverse Reactions]. The relative contribution of these concomitant medications versus ACTEMRA to thedevelopment of GI perforations is not known.Laboratory ParametersNeutrophilsTreatment with ACTEMRA was associated with a higher incidence of neutropenia. Infections have been uncommonly reportedin association with treatment-related neutropenia in long-term extension studies and postmarketing clinical experience.– It is not recommended to initiate ACTEMRA treatment in patients with a low neutrophil count ie, absolute neutrophil count (ANC) ULN to 3x ULN 22 26 34 41 17> 3x ULN to 5x ULN 0.3 2 1 2 0.3> 5x ULN 0.7 0.4 0.1 0.2 < 0.1ALT (U/L)> ULN to 3x ULN 36 33 45 48 23> 3x ULN to 5x ULN 1 4 5 5 1> 5x ULN 0.7 1 1.3 1.5 0.3ULN = Upper Limit of Normal.LipidsElevations in lipid parameters (total cholesterol, LDL, HDL, triglycerides), were first assessed at 6 weeks following initiation ofACTEMRA in the controlled 6-month clinical trials. Increases were observed at this time point and remained stable thereafter.Increases in triglycerides to levels above 500 mg/dL were rarely observed. Changes in other lipid parameters from baseline toweek 24 were evaluated and are summarized below:– Mean LDL increased by 13 mg/dL in the TCZ 4 mg/kg + DMARD arm, 20 mg/dL in the TCZ 8 mg/kg + DMARD, and 25 mg/dLin TCZ 8 mg/kg monotherapy.– Mean HDL increased by 3 mg/dL in the TCZ 4 mg/kg + DMARD arm, 5 mg/dL in the TCZ 8 mg/kg + DMARD, and 4 mg/dL inTCZ 8 mg/kg monotherapy.– Mean LDL/HDL ratio increased by an average of 0.14 in the TCZ 4 mg/kg + DMARD arm, 0.15 in the TCZ 8 mg/kg + DMARD,and 0.26 in TCZ 8 mg/kg monotherapy.– ApoB/ApoA1 ratios were essentially unchanged in patients treated with ACTEMRA.Elevated lipids responded to lipid-lowering agents.ImmunogenicityIn the 6-month, controlled clinical studies, a total of 2876 patients were tested for anti-tocilizumab antibodies. Forty-six patients(2%) developed positive anti-tocilizumab antibodies, of whom 5 had an associated medically significant hypersensitivity reactionleading to withdrawal. Thirty patients (1%) developed neutralizing antibodies.The data reflect the percentage of patients whose test results were positive for antibodies to tocilizumab in specific assays.The observed incidence of antibody positivity in an assay is highly dependent on several factors, including assay sensitivity andspecificity, assay methodology, sample handling, timing of sample collection, concomitant medication, and underlying disease.

ACTEMRA ® (tocilizumab)For these reasons, comparison of the incidence of antibodies to tocilizumab with the incidence of antibodies to other productsmay be misleading.MalignanciesDuring the 6-month, controlled period of the studies, 15 malignancies were diagnosed in patients receiving ACTEMRA,compared to 8 malignancies in patients in the control groups. Exposure-adjusted incidence was similar in the ACTEMRAgroups (1.32 events per 100 patient-years) and in the placebo plus DMARD group (1.37 events per 100 patient-years).In the all-exposure population, the rate of malignancies remained consistent (1.10 events per 100 patient-years) with therate observed in the 6-month controlled period [see Warnings and Precautions].Other Adverse ReactionsAdverse reactions occurring in 2% or more of patients on 4 mg/kg or 8 mg/kg ACTEMRA plus DMARD, and at least 1%greater than that observed in patients on placebo plus DMARD, are summarized in Table 2.Table 2 Adverse Reactions Occurring in at Least 2% or More of Patients on 4 mg/kg or 8 mg/kg ACTEMRA plus DMARDand at Least 1% Greater Than That Observed in Patients on Placebo plus DMARD6-Month Phase III Controlled Study PopulationACTEMRA8 mg/kgMonotherapyMethotrexateACTEMRA4 mg/kg +DMARDsACTEMRA8 mg/kg +DMARDsPlacebo +DMARDsPreferred TermN = 288 N = 284 N = 774 N = 1582 N = 1170(%)(%)(%)(%)(%)Upper Respiratory Tract Infection 7 5 6 8 6Nasopharyngitis 7 6 4 6 4Headache 7 2 6 5 3Hypertension 6 2 4 4 3ALT increased 6 4 3 3 1Dizziness 3 1 2 3 2Bronchitis 3 2 4 3 3Rash 2 1 4 3 1Mouth Ulceration 2 2 1 2 1Abdominal Pain Upper 2 2 3 3 2Gastritis 1 2 1 2 1Transaminase increased 1 5 2 2 1DRUG INTERACTIONSOther Drugs for Treatment of Rheumatoid ArthritisPopulation pharmacokinetic analyses did not detect any effect of methotrexate, nonsteroidal anti-inflammatory drugs orcorticosteroids on tocilizumab clearance.Concomitant administration of a single dose of 10 mg/kg ACTEMRA with 10-25 mg MTX once weekly had no clinically significanteffect on MTX exposure.ACTEMRA has not been studied in combination with biological DMARDs such as TNF antagonists [see Dosage and Administration].Interactions with CYP450 SubstratesIn vivo studies with omeprazole, metabolized by CYP2C19 and CYP3A4, and simvastatin, metabolized by CYP3A4, showed upto a 28% and 57% decrease in exposure one week following a single dose of ACTEMRA, respectively. The effect of tocilizumabon CYP enzymes may be clinically relevant for CYP450 substrates with narrow therapeutic index, where the dose is individuallyadjusted. Upon initiation or discontinuation of ACTEMRA, in patients being treated with these types of medicinal products,therapeutic monitoring of effect (eg, warfarin) or drug concentration (eg, cyclosporine or theophylline) should be performedand the individual dose of the medicinal product adjusted as needed. Prescribers should exercise caution when ACTEMRA iscoadministered with CYP3A4 substrate drugs where decrease in effectiveness is undesirable, eg, oral contraceptives, lovastatin,atorvastatin, etc. The effect of tocilizumab on CYP450 enzyme activity may persist for several weeks after stopping therapy.Live VaccinesLive vaccines should not be given concurrently with ACTEMRA [see Warnings and Precautions].USE IN SPECIFIC POPULATIONSPregnancyTeratogenic Effects. Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women.ACTEMRA should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.An embryo-fetal developmental toxicity study was performed in which pregnant cynomolgus monkeys were treated intravenouslywith tocilizumab (daily doses of 2, 10, or 50 mg/kg from gestation day 20-50) during organogenesis. Although there was noevidence for a teratogenic/dysmorphogenic effect at any dose, tocilizumab produced an increase in the incidence ofACTEMRA ® (tocilizumab)abortion/embryo-fetal death at 10 mg/kg and 50 mg/kg doses (1.25 and 6.25 times the human dose of 8 mg/kg every4 weeks based on a mg/kg comparison).Nonteratogenic Effects.Testing of a murine analogue of tocilizumab in mice did not yield any evidence of harm to offspring during the pre- and postnataldevelopment phase when dosed at 50 mg/kg intravenously with treatment every three days from implantation until day 21after delivery (weaning). There was no evidence for any functional impairment of the development and behavior, learning ability,immune competence and fertility of the offspring.Pregnancy Registry:To monitor the outcomes of pregnant women exposed to ACTEMRA, a pregnancy registry has been established. Physicians areencouraged to register patients and pregnant women are encouraged to register themselves by calling 1-877-311-8972.Nursing MothersIt is not known whether tocilizumab is excreted in human milk or absorbed systemically after ingestion. Because many drugs areexcreted in human milk, and because of the potential for serious adverse reactions in nursing infants from ACTEMRA, a decisionshould be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to themother.Pediatric UseSafety and effectiveness of ACTEMRA in pediatric patients have not been established.Geriatric UseOf the 2644 patients who received ACTEMRA in Studies I to V, a total of 435 rheumatoid arthritis patients were 65 years of age andolder, including 50 patients 75 years and older. The frequency of serious infection among subjects treated with ACTEMRA 65 yearsof age and older was higher than those under the age of 65. As there is a higher incidence in infections in the elderly population ingeneral, caution should be used when treating the elderly.Hepatic ImpairmentThe safety and efficacy of ACTEMRA have not been studied in patients with hepatic impairment, including patients with positiveHBV and HCV serology [see Warnings and Precautions].Renal ImpairmentNo dose adjustment is required in patients with mild renal impairment. ACTEMRA has not been studied in patients with moderateto severe renal impairment.OVERDOSAGEThere are limited data available on overdoses with ACTEMRA. One case of accidental overdose was reported in which a patientwith multiple myeloma received a dose of 40 mg/kg. No adverse drug reactions were observed. No serious adverse drug reactionswere observed in healthy volunteers who received single doses of up to 28 mg/kg, although all 5 patients at the highest dose of28 mg/kg developed dose-limiting neutropenia.In case of an overdose, it is recommended that the patient be monitored for signs and symptoms of adverse reactions. Patientswho develop adverse reactions should receive appropriate symptomatic treatment.PATIENT COUNSELING INFORMATIONPatient CounselingPatients should be advised of the potential benefits and risks of ACTEMRA. Physicians should instruct their patients to read theMedication Guide before starting ACTEMRA therapy.• Infections:Inform patients that ACTEMRA may lower their resistance to infections. Instruct the patient of the importance of contacting theirdoctor immediately when symptoms suggesting infection appear in order to assure rapid evaluation and appropriate treatment.• Gastrointestinal Perforation:Inform patients that some patients who have been treated with ACTEMRA have had serious side effects in the stomach andintestines. Instruct the patient of the importance of contacting their doctor immediately when symptoms of severe, persistentabdominal pain appear to assure rapid evaluation and appropriate treatment.Genentech USA, Inc., A Member of the Roche GroupSouth San Francisco, California 94080-4990Copyright © 2011 Genentech USA, Inc. All rights reserved.ACT0000394200

2200 Lake Boulevard NEAtlanta, GA 30319www.rheumatology.orgto the premier meeting in rheumatologyWWW.RHEUMATOLOGY.ORG/ANNUAL